Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop (scientific article)

cites work (P2860)

Q78724537	"-but who is that on the other side of you?" Extracampine hallucinations revisited
Q39615532	(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A compa
Q36810006	(123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study.
Q48278741	100 years of Lewy pathology
Q24194742	11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)
Q24201039	11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)
Q33188355	14-3-3 proteins in the nervous system
Q53397876	16-Year Survival of the Canadian Collaborative Cohort of Related Dementias.
Q24186399	18 F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)
Q26472008	18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)
Q47209563	18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Q47209544	18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Q47209556	18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Q55359027	18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.
Q37150637	1H magnetic resonance spectroscopy in dementia
Q48856920	69-year-old man with gait disturbance and Parkinsonism.
Q53220706	80-Year-old woman with dementia and parkinsonism.
Q91655792	A Comparative Study of Pathological Outcomes in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age and Brains for Dementia Research Cohorts
Q47389795	A Focus on the Beneficial Effects of Alpha Synuclein and a Re-appraisal of Synucleinopathies
Q36460985	A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease
Q41325603	A Novel Plasma Based Biomarker of Alzheimer's Disease
Q51900269	A Quick Test for Cognitive Speed: a measure of cognitive speed in dementia with Lewy bodies.
Q89483146	A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment
Q35702861	A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology
Q35953314	A Validation Study of the Japanese Version of the Addenbrooke's Cognitive Examination-Revised
Q42778484	A case of dementia with Lewy bodies that temporarily showed symptoms similar to Creutzfeldt-Jakob disease
Q44924042	A case study in the treatment of dementia with Lewy bodies
Q28362147	A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies
Q37598503	A clinico-pathological study of subtypes in Parkinson's disease
Q54166132	A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.
Q44790322	A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies.
Q38152390	A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review
Q45982741	A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease.
Q48708286	A comparison of sleep profiles in patients with dementia with lewy bodies and Alzheimer's disease.
Q46704118	A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
Q37204046	A critical reappraisal of current staging of Lewy-related pathology in human brain
Q31919970	A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes
Q36226890	A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry
Q49018135	A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease.
Q43580853	A neuropathological study of the disturbance of the nigro-amygdaloid connections in brains from patients with dementia with Lewy bodies
Q35572320	A neuropathological study of vascular factors in late-life depression
Q58709766	A new visual rating scale for Ioflupane imaging in Lewy body disease
Q34203072	A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease
Q34005558	A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder
Q39133398	A pilot randomised controlled trial to compare changes in quality of life for participants with early diagnosis dementia who attend a 'Living Well with Dementia' group compared to waiting-list control.
Q37184470	A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease
Q44053455	A positive association between 5HT re-uptake binding sites and depression in dementia with Lewy bodies.
Q36203534	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands
Q57914570	A psychophysiological investigation of fluctuating consciousness in neurodegenerative dementias
Q33698975	A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease
Q41289143	A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.
Q34601884	A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia
Q51940811	A registry-based, case-control investigation of Parkinson's disease with and without cognitive impairment.
Q36917620	A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer's disease and Parkinson's disease with dementia
Q36118555	A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia
Q34045764	A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia
Q48098461	A sporadic case of Creutzfeldt-Jakob disease with beta-amyloid deposits and alpha-synuclein inclusions
Q36206067	A systematic review of prevalence studies of dementia in Parkinson's disease
Q37342379	A three-year follow-up on the efficacy of psychosocial interventions for patients with mild dementia and their caregivers: the multicentre, rater-blinded, randomised Danish Alzheimer Intervention Study (DAISY).
Q45754401	A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration
Q35062331	ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients
Q51888219	APOE-epsilon4 polymorphism and cognitive deficit among the elderly population of Fernando de Noronha.
Q51940985	Abnormal fronto-parietal coupling of brain rhythms in mild Alzheimer's disease: a multicentric EEG study.
Q45191523	Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/phospholipase C (PLCbeta1) interactions
Q48545830	Abnormal sleep architecture is an early feature in the E46K familial synucleinopathy
Q36407197	Abnormalities of Cortical Neural Synchronization Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases: An EEG Study
Q46524557	Abolishing the 1-year rule: How much evidence will be enough?
Q35117248	Accounting for functional loss in Alzheimer's disease and dementia with Lewy bodies: beyond cognition
Q35456966	Accumulation of NACP/alpha-synuclein in lewy body disease and multiple system atrophy
Q74107907	Accumulation of human alpha-synuclein in different cytoskeletons in Lewy bodies in brains of dementia with Lewy bodies
Q38966914	Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo
Q48266774	Accumulation of phosphorylated alpha-synuclein in aging human brain
Q36031919	Accuracy and sensitivity of Parkinsonian disorder diagnoses in two Swedish national health registers
Q48616513	Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology
Q33650561	Acetylcholine in mind: a neurotransmitter correlate of consciousness?
Q53377858	Actigraphic measurement of agitated behaviour in dementia.
Q48826947	Acute tryptophan depletion and Lewy body dementias.
Q31033082	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia
Q48420736	Advances in molecular imaging for the diagnosis of dementia
Q35746402	Advocacy, education, and the role of not-for-profit organizations in Lewy body dementias
Q36479060	African ancestry protects against Alzheimer's disease-related neuropathology
Q36942274	Age and apoE associations with complex pathologic features in Alzheimer's disease
Q48394376	Age at onset and language disturbances in Alzheimer's disease
Q35236545	Age-related mild cognitive deficit: a ready-to-use concept?
Q34873879	Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease
Q35764504	Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
Q36175497	Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons
Q45053317	Alleviation of multiple abnormalities by galantamine treatment in two patients with dementia with Lewy bodies
Q48192079	Alpha-synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy
Q36043181	Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway
Q33583061	Alpha-synuclein immunohistochemistry of gastrointestinal and biliary surgical specimens for diagnosis of Lewy body disease
Q53369663	Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA).
Q33340612	Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia
Q47779956	Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study
Q53243970	Alpha-synuclein pathology is highly dependent on the case selection.
Q49097736	Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation.
Q35749928	Alpha-synuclein: normal function and role in neurodegenerative diseases.
Q35380017	Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly
Q33754643	Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity
Q48952606	Altered CpG methylation in sporadic Alzheimer's disease is associated with APP and MAPT dysregulation.
Q34093055	Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease
Q36734720	Altered mental status in older patients in the emergency department
Q46363886	Alzheimer disease and other dementias
Q33997481	Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy
Q34519925	Alzheimer's disease and other dementias: a review
Q34249305	Alzheimer's disease and related disorders
Q44267943	Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes
Q40107949	Alzheimer's disease or Alzheimer's syndrome?: a longitudinal computed tomography neuroradiological follow-up study of 56 cases diagnosed clinically as Alzheimer's disease
Q35693275	Alzheimer's disease pathology does not mediate the association between depressive symptoms and subsequent cognitive decline
Q91588056	Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE-ε4/TOMM40 long poly-T repeat allele variants
Q43738764	Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation
Q34025936	Alzheimer's disease: current knowledge, management and research
Q34349174	Alzheimer's disease: its diagnosis and pathogenesis.
Q38797714	Amygdala α-Synuclein Pathology in the Population-Based Vantaa 85+ Study.
Q55516574	Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data.
Q47950253	Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology
Q35179121	An autopsied case of dementia with Lewy bodies with supranuclear gaze palsy
Q36633738	An individualized approach to treatment for alzheimer's disease, pick's disease, and other dementias
Q34262778	An overview of common non-Alzheimer dementias
Q51458996	Anal sphincter electromyography in patients with newly diagnosed idiopathic parkinsonism.
Q58264915	Analysis of spontaneous, conversational speech in dementia of Alzheimer type: Evaluation of an objective technique for analysing lexical performance
Q48172943	Analysis of video-polysomnographic sleep findings in dementia with Lewy bodies
Q91845936	Analysis of α-synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies
Q49168413	Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.
Q46169716	Anatomical correlates of sentence comprehension and verbal working memory in neurodegenerative disease.
Q30495523	Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology
Q35484548	Anosmia is very common in the Lewy body variant of Alzheimer's disease
Q38371612	Anosognosia for memory impairment in Alzheimer's disease
Q37351280	Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia
Q46980744	Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro
Q34045304	Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses
Q48914082	Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations.
Q34431230	Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort
Q36501660	Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance
Q36558596	Approach to diagnosis of Parkinson disease.
Q34683770	Approach to managing behavioural disturbances in dementia.
Q35863410	Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?
Q37136173	Are there sensitive time periods for dementia caregivers? The occurrence of behavioral and psychological symptoms in the early stages of dementia
Q28079237	Arguing against the proposed definition changes of PD
Q48623789	Argyrophilic grain disease: frequency and neuropathology in centenarians
Q64114058	Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series
Q36510471	Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia
Q38115735	Ascertainment bias in dementias: a secondary to tertiary centre analysis in Central Italy and conceptual review
Q36593963	Assessing Fluctuating Cognition in Dementia Diagnosis: Interrater Reliability of the Clinician Assessment of Fluctuation.
Q36212058	Assessing dementia in resource-poor regions
Q44208377	Assessment of CSF homovanillic acid levels distinguishes dementia with Lewy bodies from Alzheimer's disease
Q24805277	Assessment of diffuse Lewy body disease by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET)
Q45156627	Assessment of instrumental activities of daily living in dementia: diagnostic value of the Amsterdam Instrumental Activities of Daily Living Questionnaire
Q53271204	Assessment of pharmacological toxicity using serum anticholinergic activity in a patient with dementia.
Q46990628	Assessment of regional MR diffusion changes in dementia with Lewy bodies and Alzheimer's disease
Q32122293	Assessment of suspected dementia
Q45736636	Assessment of the efficacy of early phase parameters by (123)I-MIBG dynamic imaging for distinguishing Lewy body-related diseases from Parkinson's syndrome.
Q51917340	Association between amantadine and the onset of dementia in Parkinson's disease.
Q43753407	Association between cognition and daily life functioning in dementia subtypes
Q45716360	Association between functional impairment, depression, and extrapyramidal signs in neuroleptic-free patients with Alzheimer disease
Q33829013	Association between lifetime cigarette smoking and lewy body accumulation
Q36317276	Association between medial temporal lobe atrophy on CT and parietotemporal uptake decrease on SPECT in Alzheimer's disease.
Q48860978	Association between progranulin and beta-amyloid in dementia with Lewy bodies.
Q48686296	Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy.
Q64786374	Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology
Q36395515	Association of lower hemoglobin level and neuropathology in community-dwelling older persons
Q91392201	Associations among Braak stage, Parkinsonian gait, cognition, and functional status in autopsy-confirmed dementia with Lewy bodies
Q92286200	Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer's Disease
Q91739737	Associations of amygdala volume and shape with transactive response DNA-binding protein 43 (TDP-43) pathology in a community cohort of older adults
Q53623552	Atypical parkinsonism and Annonaceae consumption in New Caledonia.
Q34575656	Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?
Q64814710	Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis
Q48579475	Auditory startle responses as a probe of brainstem function in healthy subjects and patients with movement disorders.
Q36653957	Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
Q55316079	Author's Response to the Letter to the Editor Regarding: Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives.
Q51905426	Autonomic and cognitive dysfunction in Parkinson's disease.
Q36226996	Autonomic dysfunction in dementia.
Q35624697	Autophagy in dementias
Q33946243	Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core
Q37610726	Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB.
Q36677512	Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein
Q36658992	Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein
Q34426744	Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study
Q44120239	B-type natriuretic peptide and severity of cognitive disorder
Q44889302	B-type natriuretic peptide as a predictor of declining cognitive function and dementia--a cohort study of an elderly general population with a 5-year follow-up
Q34496168	Barriers to treatment: the unique challenges for physicians providing dementia care
Q45375765	Bayer-activities of daily living scale in mild and moderate dementia of the Alzheimer type
Q36498425	Behavior management approach for agitated behavior in Japanese patients with dementia: a pilot study
Q51545497	Behavior of α-synuclein-drug complexes during nanopore analysis with a superimposed AC field.
Q51914198	Behavioral and psychologic symptoms in different types of dementia.
Q53369876	Behavioral and psychological symptoms in Alzheimer's disease: frequency and relationship with duration and severity of the disease.
Q37334238	Behavioral symptoms and caregiver burden in dementia
Q36292518	Behavioural changes and psychological symptoms in dementia disorders
Q36319091	Behavioural disturbance and visual hallucinations in a 78 year old man.
Q51909456	Behavioural disturbance triggers recognition of dementia by family informants.
Q48195204	Behavioural measures in frontotemporal lobar dementia and other dementias: the utility of the frontal behavioural inventory and the neuropsychiatric inventory in a national cohort study.
Q33539480	Behavioural problems associated with dementia: the role of newer antipsychotics
Q34716867	Benefit-risk considerations in the treatment of dementia with Lewy bodies
Q37237399	Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid
Q24684579	Beta-synuclein gene alterations in dementia with Lewy bodies
Q37284576	Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND)
Q37626451	Bilingualism does not alter cognitive decline or dementia risk among Spanish-speaking immigrants.
Q37590663	Biological fluid biomarkers in neurodegenerative parkinsonism
Q40239769	Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis.
Q33896664	Biomarkers for cognitive impairment in Parkinson disease
Q50675225	Biomarkers of vascular dysfunction and cognitive decline in patients with Alzheimer's disease: no evidence for association in elderly subjects.
Q33703477	Biomonitorization of iron accumulation in the substantia nigra from Lewy body disease patients
Q33470625	Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein
Q47845444	Blood DNA methylation as a potential biomarker of dementia: A systematic review.
Q80577193	Blood pressure and drug treatment in clinically diagnosed Lewy body dementia and Alzheimer's disease
Q53288271	Blood-based neurochemical diagnosis of vascular dementia: a pilot study.
Q50770473	Both conventional indices of cognitive function and frailty predict levels of care required in a long-term care insurance program for memory clinic patients in Japan.
Q51926701	Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging.
Q33449763	Brain bank of the Brazilian aging brain study group - a milestone reached and more than 1,600 collected brains.
Q26801644	Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants
Q31051218	Brain imaging in dementia
Q47108443	Brainstem tau pathology in Alzheimer's disease is characterized by increase of three repeat tau and independent of amyloid β.
Q48715546	Brainstem-type Lewy body disease presenting with progressive autonomic failure and lethargy.
Q35094391	Bridging molecular genetics and biomarkers in lewy body and related disorders
Q90071243	Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review
Q64878334	Butyrylcholinesterase K: an association with dementia with Lewy bodies
Q52009598	CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer's disease.
Q35006611	COGNITIVE DYSFUNCTION IN FMR1 PREMUTATION CARRIERS.
Q33239180	CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
Q57780485	CSF amyloid-β 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction
Q28731571	CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis
Q53380746	CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies.
Q36227579	CSF neurofilament proteins in the differential diagnosis of dementia
Q44247835	CSF tau and Abeta42: logical biomarkers for Alzheimer's disease?
Q24197654	CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
Q38741683	CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Q53253261	CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.
Q35757239	Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation
Q48899518	Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?
Q47344957	Can alzheimer's disease and dementias with Lewy bodies be distinguished clinically?
Q38542228	Can clock drawing differentiate Alzheimer's disease from other dementias?
Q36618103	Can we clinically diagnose dementia with Lewy bodies yet?
Q51937558	Canadian Outcomes Study in Dementia: study methods and patient characteristics.
Q46569969	Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life
Q33154006	Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias
Q89738439	Cardiac sympathetic denervation and synucleinopathy in Alzheimer's disease with brain Lewy body disease
Q47655415	Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer's disease
Q36822410	Caring for individuals with dementia and cognitive impairment, not dementia: findings from the aging, demographics, and memory study
Q33151494	Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions.
Q53668710	Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology.
Q42739339	Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson's disease and dementia with Lewy bodies
Q33994111	Cataract and cognitive impairment: a review of the literature.
Q34687641	Cell death mechanisms in neurodegeneration.
Q33877643	Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies
Q57723480	Cerebral Blood Flow by Using Pulsed Arterial Spin-Labeling in Elderly Subjects with White Matter Hyperintensities
Q41528038	Cerebral Microbleeds in Patients with Dementia with Lewy Bodies and Parkinson Disease Dementia
Q80778122	Cerebral amyloid angiopathy in Lewy body disease
Q33726557	Cerebral atherosclerosis is associated with cystic infarcts and microinfarcts but not Alzheimer pathologic changes
Q46388197	Cerebral blood flow in Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease according to three-dimensional stereotactic surface projection imaging
Q35458372	Cerebral correlates of psychotic symptoms in Alzheimer's disease
Q35194993	Cerebral correlates of psychotic syndromes in neurodegenerative diseases
Q46597682	Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations.
Q45913449	Cerebral perfusion (HMPAO-SPECT) in patients with depression with cognitive impairment versus those with mild cognitive impairment and dementia of Alzheimer's type: a semiquantitative and automated evaluation.
Q44207328	Cerebrospinal fluid and plasma concentrations of nitric oxide metabolites are increased in dementia with Lewy bodies.
Q34248241	Cerebrospinal fluid biomarkers for dementia with lewy bodies
Q36120659	Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients
Q48095120	Cerebrospinal fluid levels of amyloid beta-peptide1-42, but not tau have positive correlation with brain glucose metabolism in humans
Q33371612	Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease
Q50241761	Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies.
Q53504163	Cerebrovascular Lesions in Mixed Neurodegenerative Dementia: A Neuropathological and Magnetic Resonance Study.
Q47560023	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
Q51066366	Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimer's pathology not α-synuclein pathology.
Q36103023	Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes.
Q37038032	Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains
Q30382595	Changing perspectives regarding late-life dementia.
Q48625589	Characteristics of alpha-synucleinopathy in centenarians
Q51871751	Characteristics of eating and swallowing problems in patients who have dementia with Lewy bodies.
Q37035800	Characterization of Japanese-American men with a single neocortical AD lesion type
Q36077153	Characterizing cognitive deficits and dementia in an aging urban population in India
Q47139402	Chilean version of the INECO Frontal Screening (IFS-Ch): psychometric properties and diagnostic accuracy
Q37217895	Cholinergic components of frontal lobe function and dysfunction
Q26764933	Cholinergic imaging in dementia spectrum disorders
Q34108192	Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders
Q24244668	Cholinesterase inhibitors for Parkinson's disease dementia
Q34251448	Cholinesterase inhibitors for behavioral disturbance in dementia
Q24201307	Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease
Q24245967	Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease
Q42610667	Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.
Q73365330	Cholinesterase inhibitors: expanding applications
Q44807722	Cholinesterase-inhibitor therapy for dementia: novel clinical substrates and mechanisms for treatment response
Q39356552	Choto-san versus placebo for patients with dementia: systematic review and meta-analysis
Q46354633	Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations
Q53281587	Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles.
Q53380312	Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
Q45934882	Classification of delusions in Alzheimer's disease and their neural correlates.
Q35850390	Clinical Features of Alzheimer Disease With and Without Lewy Bodies
Q53232551	Clinical Lewy body dementia and the impact of vascular components.
Q35105734	Clinical Manifestations of Parkinson's Disease and Parkinsonism
Q46018564	Clinical Phenotype of Adult Fragile X Gray Zone Allele Carriers: a Case Series.
Q33166368	Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease.
Q48647976	Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies
Q36295239	Clinical and neuroimaging characteristics of Chinese dementia with Lewy bodies
Q48311450	Clinical and neuropsychological features associated with structural imaging patterns in patients with mild cognitive impairment
Q33638836	Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status
Q37151773	Clinical and pathological features of an Alzheimer's disease patient with the MAPT Delta K280 mutation
Q35068733	Clinical application of positron emission tomography for diagnosis of dementia
Q81651118	Clinical aspects of dementia with Lewy bodies
Q42527156	Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease
Q48476359	Clinical correlates of the pathology underlying parkinsonism: a population perspective
Q74549410	Clinical diagnosis of dementia with Lewy bodies
Q21710734	Clinical differentiation of parkinsonian syndromes: Prognostic and therapeutic relevance
Q34554039	Clinical features and assessment of severe dementia. A review
Q64117662	Clinical impact of [F]flutemetamol PET among memory clinic patients with an unclear diagnosis
Q57307017	Clinical judgement by primary care physicians for the diagnosis of all-cause dementia or cognitive impairment in symptomatic people
Q34264188	Clinical overview of the synucleinopathies
Q28280248	Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene
Q36632771	Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology
Q37810697	Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology
Q44610471	Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle
Q38154832	Clinical presentation and differential diagnosis of dementia with Lewy bodies: a review
Q49962915	Clinical prevalence of Lewy body dementia.
Q36806669	Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies
Q36321516	Clinical utility of resting-state functional connectivity magnetic resonance imaging for mood and cognitive disorders
Q36632706	Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
Q28393370	Clinical-pathologic study of depressive symptoms and cognitive decline in old age
Q35106476	Clinicians' ability to diagnose dementia with Lewy bodies is not affected by β-amyloid load
Q48212849	Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series
Q35923461	Clinico-pathological correlations of the most common neurodegenerative dementias.
Q37100913	Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder
Q40069625	Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010.
Q37052334	Clinicopathologic study of Alzheimer's disease: Alzheimer mimics
Q38559217	Clinicopathological characteristics of freezing of gait in autopsy-confirmed Parkinson's disease
Q34345893	Clinicopathological correlates in frontotemporal dementia
Q37860194	Clinicopathological correlates of behavioral and psychological symptoms of dementia
Q36574153	Clinicopathological correlation of psychosis and brain vascular changes in Alzheimer's disease
Q33997776	Clinicopathological studies on diffuse Lewy body disease
Q42436185	Close relationship between spongiform change and ubiquitin-positive granular structures in diffuse Lewy body disease
Q44396203	Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons.
Q89161085	Codon Usage Pattern of Genes Involved in Central Nervous System
Q37247810	Coexistence of Creutzfeldt-Jakob disease, Lewy body disease, and Alzheimer's disease pathology: an autopsy case showing typical clinical features of Creutzfeldt-Jakob disease
Q35169121	Cognition and neuropathology in aging: multidimensional perspectives from the Rush Religious Orders Study and Rush Memory And Aging Project
Q57300698	Cognition, Olfaction and Uric Acid in Early de novo Parkinson's Disease
Q51825935	Cognitive Domain Dispersion Association with Alzheimer's Disease Pathology.
Q47923287	Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias
Q38418449	Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients
Q36225061	Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewski's description of PSP 40 years ago and Albert's delineation of the subcortical dementia 30 years ago.
Q34957392	Cognitive and motor symptoms in dementia: focus on dementia with Lewy bodies
Q51903177	Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study.
Q58751300	Cognitive composite score association with Alzheimer's disease plaque and tangle pathology
Q48149818	Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson's disease with dementia
Q34806323	Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both
Q45740245	Cognitive effects of quetiapine in a patient with dementia with Lewy bodies
Q49873853	Cognitive fluctuations in Parkinson's disease dementia: blood pressure lability as an underlying mechanism.
Q35240304	Cognitive fluctuations in connection to dysgraphia: a comparison of Alzheimer's disease with dementia Lewy bodies.
Q35750397	Cognitive impact of subcortical vascular and Alzheimer's disease pathology
Q36244575	Cognitive impairment and dementia in basal ganglia disorders
Q77348504	Cognitive impairment in Parkinson's disease
Q34245237	Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group
Q36315342	Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies
Q82251334	Cognitive impairments in progression of Parkinson's disease
Q33585781	Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites
Q92603946	Cognitive training for people with mild to moderate dementia
Q44610473	Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia
Q37001170	Cognitive-behavioral profiles of neurodegenerative dementias: beyond Alzheimer's disease
Q50659882	Cohort profile: the Health and Memory Study (HMS): a dementia cohort linked to the HUNT study in Norway.
Q44032768	Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles
Q34193835	Colocalization of Tau and Alpha-Synuclein Epitopes in Lewy Bodies
Q53299129	Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.
Q89259517	Combined neuropathological pathways account for age-related risk of dementia
Q46291223	Combining functional scales and cognitive tests in screening for mild cognitive impairment at a university-based memory clinic in Brazil
Q48785723	Commentary: DLB and PDD: the same or different? Is there a debate?
Q38410806	Comparative analysis of cognitive impairments in lewy body dementia and Alzheimer's disease.
Q34151383	Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain
Q40992216	Comparative quantitative study of 'signature' pathological lesions in the hippocampus and adjacent gyri of 12 neurodegenerative disorders
Q46836076	Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease
Q33636257	Comparing Cerebral White Matter Lesion Burdens between Parkinson's Disease with and without Dementia
Q37330079	Comparing Cognitive Profiles of Licensed Drivers with Mild Alzheimer's Disease and Mild Dementia with Lewy Bodies.
Q51918910	Comparison between two tests of delayed recall for the diagnosis of dementia.
Q45088809	Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies
Q79892702	Comparison of behavioral and psychological symptoms in early-onset and late-onset Alzheimer's disease
Q37078913	Comparison of clinical manifestations in Alzheimer disease and dementia with Lewy bodies
Q35899470	Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study
Q36808790	Comparison of costs of care between patients with Alzheimer's disease and dementia with Lewy bodies
Q52003053	Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.
Q36665371	Comparison of informal care time and costs in different age-related dementias: a review
Q46890602	Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies.
Q53271928	Complexity of work and risk of Alzheimer's disease: a population-based study of Swedish twins.
Q46160303	Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP.
Q24599735	Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease
Q38311234	Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies
Q33583920	Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis
Q35181136	Conscientiousness, dementia related pathology, and trajectories of cognitive aging
Q57306418	Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
Q33600226	Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years
Q43289210	Construction of a (18)F-FDG PET normative database of Japanese healthy elderly subjects and its application to demented and mild cognitive impairment patients
Q35088093	Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies
Q33704308	Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD).
Q48761776	Corpus callosum in neurodegenerative diseases: findings in Parkinson's disease.
Q35749788	Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia
Q47748535	Correlation between clinical symptoms and striatal DAT uptake in patients with DLB.
Q51217722	Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies.
Q37382788	Correlation of clinical features with argyrophilic grains at autopsy
Q51935133	Correlation of entorhinal amyloid with memory in Alzheimer's and vascular but not Lewy body dementia.
Q36592191	Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques
Q74265319	Cortical Lewy bodies
Q40364232	Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases
Q40780818	Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study
Q48456793	Cortical myoclonus in levodopa-responsive parkinsonism
Q42508033	Corticobasal syndrome with tau pathology
Q90046619	Corticobasal syndrome with visual hallucinations and probable REM-sleep behavior disorder: an autopsied case report of a patient with CBD and LBD pathology
Q90285295	Cough reflex sensitivity and urge-to-cough deterioration in dementia with Lewy bodies
Q48467717	Course and causes of suspected dementia in young adults: a longitudinal study
Q48371182	Covariance 99mTc-exametazime SPECT patterns in Alzheimer's disease and dementia with Lewy bodies: utility in differential diagnosis
Q37284415	Covariant perfusion patterns provide clues to the origin of cognitive fluctuations and attentional dysfunction in dementia with Lewy bodies
Q33760744	CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease
Q30414507	Creativity and dementia: a review
Q73257348	Criteria for the clinical diagnosis of dementia with Lewy bodies
Q37585420	Cross currents in protein misfolding disorders: interactions and therapy
Q37217977	Current and future management of the corticobasal syndrome and corticobasal degeneration
Q31143267	Current and future uses of neuroimaging for cognitively impaired patients
Q34566312	Current management of sleep disturbances in dementia
Q61903306	Current perspectives in dementia with Lewy bodies
Q35540208	Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease
Q35570834	Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies
Q73755349	Cyclin-dependent kinase 5 (Cdk5) associated with Lewy bodies in diffuse Lewy body disease
Q43794661	Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo
Q55384256	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier.
Q88947098	Dealing with severe dementia in clinical practice: A validity and reliability study of Severe Mini-Mental State Examination in Greek population
Q48398251	Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study
Q42756359	Decline in cognitive function in Parkinson's disease may be due to dementia with Lewy bodies
Q48022171	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias.
Q44677193	Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease
Q45993148	Decreased ventilatory response to hypercapnia in dementia with Lewy bodies.
Q34596395	Deep brain stimulation for Parkinson's disease: patient selection and evaluation
Q36524109	Deep brain stimulation: preoperative issues
Q48212869	Defining mild cognitive impairment in Parkinson's disease
Q34402731	Degeneration of brainstem respiratory neurons in dementia with Lewy bodies
Q44388400	Degeneration of tyrosine hydroxylase-immunoreactive neurons in the cerebral cortex and hippocampus of patients with dementia with Lewy bodies
Q73816088	Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein-immunohistochemistry
Q48315686	Degenerative terminals of the perforant pathway are human alpha-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease
Q37004135	Delirium in the older emergency department patient: a quiet epidemic
Q73209980	Delusions in Alzheimer's disease: spet evidence of right hemispheric dysfunction
Q55286722	Delusions in Patients with Dementia with Lewy Bodies and the Associated Factors.
Q26860881	Dementia
Q77658687	Dementia
Q36422185	Dementia and its implications for public health
Q37222701	Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population
Q43542370	Dementia and oral health among subjects aged 75 years or older
Q35172297	Dementia associated with Parkinson's disease
Q37334206	Dementia clinic in general hospital settings
Q83774128	Dementia in Parkinson's disease
Q48721559	Dementia in Parkinson's disease challenges the "gold standard".
Q48923189	Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency.
Q36022100	Dementia in idiopathic Parkinson's syndrome
Q84777657	Dementia in parkinsonism
Q36787352	Dementia syndromes: evaluation and treatment
Q34811582	Dementia with Lewy Bodies versus Alzheimer's Disease and Parkinson's Disease Dementia: A Comparison of Cognitive Profiles
Q37694473	Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms.
Q57306397	Dementia with Lewy bodies
Q74595912	Dementia with Lewy bodies
Q79328891	Dementia with Lewy bodies
Q80690619	Dementia with Lewy bodies
Q82238580	Dementia with Lewy bodies
Q90597056	Dementia with Lewy bodies - from scientific knowledge to clinical insights
Q35474145	Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older
Q34208554	Dementia with Lewy bodies in Down's syndrome
Q39703602	Dementia with Lewy bodies is associated with higher scores on the Geriatric Depression Scale than is Alzheimer's disease
Q44609329	Dementia with Lewy bodies versus Alzheimer's disease: Role of dopamine transporter imaging
Q33768344	Dementia with Lewy bodies versus nonconvulsive status epilepticus in the diagnosis of a patient with cognitive dysfunction, complex visual hallucinations and periodic abnormal waves in EEG: a case report
Q30586107	Dementia with Lewy bodies.
Q35573865	Dementia with Lewy bodies. Review of diagnosis and pharmacologic management
Q24657382	Dementia with Lewy bodies: Definition, diagnosis, and pathogenic relationship to Alzheimer's disease
Q36226812	Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy.
Q61446034	Dementia with Lewy bodies: an update and outlook
Q35029466	Dementia with Lewy bodies: clinical characteristics and diagnostic criteria.
Q34289869	Dementia with Lewy bodies: clinical features and treatment
Q48766635	Dementia with Lewy bodies: clustering of Lewy bodies in human patients.
Q30667144	Dementia with Lewy bodies: diagnosis and management
Q35191667	Dementia with Lewy bodies: disease concept and genetics
Q35029472	Dementia with Lewy bodies: neuropathology
Q53261140	Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease.
Q47144691	Dementia with Parkinson disease: Clinical diagnosis, neuropsychological aspects and treatment
Q35703007	Dementia with lewy bodies: diagnosis and management for primary care providers
Q51971473	Dementia with lewy bodies: findings from an international multicentre study.
Q35863395	Dementia with lewy bodies: molecular pathogenesis and implications for classification
Q45022206	Dementia-current knowledge and significance for ENT specialists
Q30404451	Dementia.
Q34554963	Dementia: a neuroendocrine perspective
Q41684963	Dementias that present with and without posterior cortical features: an important clinical distinction
Q42489585	Depletion of cholinergic neurons in the nucleus of the medial septum and the vertical limb of the diagonal band in dementia with Lewy bodies
Q51927592	Depression and associated factors of informal caregivers versus professional caregivers of demented patients.
Q45928607	Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy.
Q53234942	Depression in the carers of dementia sufferers: a comparison of the carers of patients suffering from dementia with Lewy bodies and the carers of patients with Alzheimer's disease.
Q36960697	Description of microcolumnar ensembles in association cortex and their disruption in Alzheimer and Lewy body dementias
Q48250486	Detailed electroencephalographic long-term follow-up study in Lewy body dementia with periodic sharp wave complexes
Q44143951	Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.
Q48558074	Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease
Q34691754	Development and screening of contrast agents for in vivo imaging of Parkinson's disease
Q90733104	Development and validation of a screening instrument for cognitive fluctuation in patients with neurocognitive disorder with Lewy bodies (NCDLB): the Mayo Fluctuations Scale-Thai version
Q45863093	Development of a novel FMRI compatible visual perception prototype battery to test older people with and without dementia.
Q33650931	Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study.
Q48299267	Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies
Q99240071	Diabetes as a Risk Factor for Abnormal Cognition Development
Q36832420	Diagnosing Alzheimer's disease--non-clinicians and computerised algorithms together are as accurate as the best clinical practice
Q33751527	Diagnosing dementia with Lewy bodies
Q35236236	Diagnosis and management of Alzheimer's disease
Q33869820	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
Q41612700	Diagnosis and staging of Alzheimer disease
Q46431181	Diagnosis of Alzheimer's disease using brain perfusion SPECT and MR imaging: which modality achieves better diagnostic accuracy?
Q33601574	Diagnosis of dementia and treatment of Alzheimer's disease. Pharmacologic management of disease progression and cognitive impairment
Q36074760	Diagnosis of dementia with Lewy bodies in clinical practice: a literature review
Q48413371	Diagnosis of dementia with Lewy bodies: can 123I-IMP and 123I-MIBG scintigraphy yield new core features?
Q35789236	Diagnosis of dementia with Lewy bodies: diagnostic performance of combined ¹²³I-IMP brain perfusion SPECT and ¹²³I-MIBG myocardial scintigraphy
Q34174197	Diagnosis, classification and natural history of degenerative dementias
Q48122199	Diagnostic Significance of Cortical Superficial Siderosis for Alzheimer Disease in Patients with Cognitive Impairment
Q50666330	Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Q35203115	Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study
Q36806592	Diagnostic criteria of dementia
Q39051531	Diagnostic imaging of dementia with Lewy bodies by susceptibility-weighted imaging of nigrosomes versus striatal dopamine transporter single-photon emission computed tomography: a retrospective observational study.
Q48404632	Diagnostic utility of the Pittsburgh Sleep Quality Index in memory clinics
Q52380787	Did Don Quixote have Lewy body disease?
Q48964060	Differences in MR features of the substantia innominata between dementia with Lewy bodies and Alzheimer's disease.
Q43911586	Differences in clinical course between dementia with Lewy bodies and Alzheimer's disease
Q44908766	Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients
Q50769270	Differences in survival between patients with dementia with Lewy bodies and patients with Alzheimer's disease--measured from a fixed cognitive level.
Q58794529	Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer's disease brains: Implications for in-vivo diagnostics
Q37392690	Different molecular pathologies result in similar spatial patterns of cellular inclusions in neurodegenerative disease: a comparative study of eight disorders
Q33545288	Differential diagnosis of Parkinson's disease
Q50848165	Differential diagnosis of degenerative dementias using basic neuropsychological tests: multivariable logistic regression analysis of 301 patients.
Q31082974	Differential diagnosis of neurodegenerative diseases using structural MRI data
Q44806592	Differential diagnosis of parkinsonism using dopamine transporters brain SPECT
Q48099912	Differential nigral expression of bcl-2 protein family in the pure and common forms of Dementia with Lewy bodies: relevance for dopaminergic neuronal vulnerability
Q36961555	Differential patterns of hypoperfusion in subtypes of mild cognitive impairment
Q34572608	Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease
Q34636958	Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography
Q35468295	Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand
Q53269086	Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT.
Q51963250	Diffuse Lewy Body Disease.
Q34063880	Diffuse Lewy body disease
Q33775778	Diffuse Lewy body disease: clinical, pathological, and neuropsychological review
Q33726660	Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies
Q47617284	Discrepancy between self- and proxy-rated pain in Alzheimer's disease: results from the Danish Alzheimer Intervention Study
Q36744396	Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration
Q43806064	Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study
Q48445681	Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex
Q36444633	Divergent brain functional network alterations in dementia with Lewy bodies and Alzheimer's disease
Q47726572	Do Individual and Geographical Deprivation Have the Same Impact on the Risk of Dementia? A 25-Year Follow-up Study.
Q30697738	Do brain T2/FLAIR white matter hyperintensities correspond to myelin loss in normal aging? A radiologic-neuropathologic correlation study
Q62066265	Do community-dwelling Māori and Pacific peoples present with dementia at a younger age and at a later stage compared with NZ Europeans?
Q79829273	Do family caregivers perceive more difficulty when they look after patients with early onset dementia compared to those with late onset dementia?
Q35166684	Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature
Q38067885	Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology?
Q48436163	Does posterior cortical atrophy on MRI discriminate between Alzheimer's disease, dementia with Lewy bodies, and normal aging?
Q48485959	Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?
Q45789315	Donepezil abolishes anticholinergic activity in a patient with amnesia
Q35144642	Donepezil and life expectancy in Alzheimer's disease: a retrospective analysis in the Tajiri Project
Q35467921	Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
Q36419270	Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial
Q35114379	Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial
Q50745621	Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
Q46605175	Dopamine D2 receptor plays a role in memory function: implications of dopamine-acetylcholine interaction in the ventral hippocampus
Q24186395	Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies
Q24201437	Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies
Q37624612	Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies
Q24685507	Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis
Q44236057	Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia
Q38814843	Drawing Disorders in Alzheimer's Disease and Other Forms of Dementia
Q33588025	Driving Retirement in Older Adults with Dementia
Q34541058	Driving cessation and dementia: results of the prospective registry on dementia in Austria (PRODEM).
Q34463831	Dysautonomia in Parkinson disease
Q43763456	EEG evidence of posterior cortical disconnection in PD and related dementias.
Q53295999	EEG spectral analysis in Alzheimer's disease and different degenerative dementias.
Q51959225	Early detection of patients in the pre demented stage of Alzheimer's disease: the Pre-Al Study.
Q46538558	Early neuropsychological discriminants for Lewy body disease: an autopsy series
Q51766224	Early stages of Alzheimer's disease are alarming signs in injury deaths caused by traffic accidents in elderly people (≥60 years of age): A neuropathological study.
Q35678247	Early visuospatial deficits predict the occurrence of visual hallucinations in autopsy-confirmed dementia with Lewy bodies
Q45245254	Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease
Q36141974	Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.
Q36355206	Effectiveness of Electroconvulsive Therapy for Depression and Cotard's Syndrome in a Patient with Frontotemporal Lobe Dementia
Q33267768	Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies.
Q46342133	Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies
Q50113462	Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study.
Q51905179	Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
Q45973827	Efficacy and safety of memantine in Lewy body dementia.
Q33930367	Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
Q38901204	Electroencephalographic markers in dementia
Q40782309	Electrophysiological observations in hereditary parkinsonism-dementia with Lewy body pathology
Q35809798	Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism.
Q37209166	Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient
Q37585464	Enhancing attention in neurodegenerative diseases: current therapies and future directions.
Q33904779	Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis
Q28471701	Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study
Q64785198	Episodic recognition memory and the hippocampus in Parkinson's disease: A review
Q35553096	Essentials of the Proper Diagnoses of Mild Cognitive Impairment, Dementia, and Major Subtypes of Dementia
Q31036797	Estimating the prevalence of Parkinson's disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data.
Q34303494	Estimating the temporal evolution of Alzheimer's disease pathology with autopsy data
Q44762763	Etiologies of Parkinsonism in a century-long autopsy-based cohort
Q38085606	European studies on the prevalence of dementia in the elderly: time for a step towards a methodological consensus
Q30488694	Evaluation of alpha-synuclein immunohistochemical methods used by invited experts
Q38014888	Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?
Q35451757	Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study
Q43701456	Evidence for modest familial co-aggregation between dementia and parkinsonism
Q33816311	Evidence for the involvement of apoptosis-inducing factor-mediated caspase-independent neuronal death in Alzheimer disease
Q46686665	Evidence of oxidative stress in the neocortex in incidental Lewy body disease
Q57629694	Executive Functioning
Q35706431	Executive deficits are related to the inferior frontal junction in early dementia
Q51895787	Executive dysfunction using behavioral assessment of the dysexecutive syndrome in Parkinson's disease.
Q43694138	Expression of alpha-synuclein in the human brain: relation to Lewy body disease.
Q53372813	Expression of cellular prion protein in the frontal and occipital lobe in Alzheimer's disease, diffuse Lewy body disease, and in normal brain: an immunohistochemical study.
Q37601806	FMR1 gray-zone alleles: association with Parkinson's disease in women?
Q35106553	Factors associated with cognitive evaluations in the United States.
Q44489283	Factors associated with drug-induced visual hallucinations in Parkinson's disease
Q36318201	Factors associated with psychotic symptoms in Alzheimer's disease
Q35029476	Familial Lewy body diseases
Q35712599	Familial aggregation of dementia with Lewy bodies
Q34181358	Familial and sporadic Parkinson's disease usually display the same clinical features
Q34696605	Familial dementia with Lewy bodies with an atypical clinical presentation
Q34696623	Familial occurrence of dementia with Lewy bodies
Q48614789	Familial parkinsonism, dementia, and Lewy body disease: study of family G.
Q35977445	Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases
Q36387325	Fifty Percent Prevalence of Extracampine Hallucinations in Parkinson's Disease Patients
Q34145432	Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity
Q50265321	First report of a pathogenic mutation on exon 24 of the NOTCH3 gene in a CADASIL family.
Q35479873	Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct
Q79964392	Fluctuations in cognitive function in dementia with Lewy bodies
Q37329050	Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study
Q40629446	Freezing of gait in postmortem-confirmed atypical parkinsonism
Q51903764	Frequency and clinical characteristics of early-onset dementia in consecutive patients in a memory clinic.
Q36643547	Frequency and course of mild cognitive impairment in a multiethnic community
Q53246690	Frequency and distribution of TUNEL-positive neurons in brains of dementia with Lewy bodies: comparison with those in brains of Alzheimer's disease.
Q50053711	Frequency of Cardiovascular Genetic Risk Factors in a Calabrian Population and Their Effects on Dementia.
Q46708090	Frequency of dementia etiologies in four ethnic groups
Q86832605	Frequency of dementia syndromes with a potentially treatable cause in geriatric in-patients: analysis of a 1-year interval
Q43532439	Frequency of early and late-onset dementias in a Japanese memory disorders clinic
Q64861832	Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease
Q51928216	From mild cognitive impairment to dementia: a prevalence study in a district of Tuscany, Italy.
Q46836071	From the heart to the brain via cardiac MIBG imaging
Q48651369	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy.
Q36318191	Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia
Q42442434	Frontotemporal and motor neurone degeneration with neurofilament inclusion bodies: additional evidence for overlap between FTD and ALS.
Q48587961	Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease
Q37069848	Frontotemporal dementia: clinicopathological correlations
Q48264359	Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP.
Q48475636	Fulminant Lewy body disease
Q51899491	Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease.
Q35751834	Functional brain imaging in the differential diagnosis of Parkinson's disease
Q37003575	Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer's disease
Q35112517	Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD.
Q37979978	Gaucher disease and the synucleinopathies: refining the relationship
Q38906744	Gender difference in the association and presentation of visual hallucinations in dementia with Lewy bodies: a cross-sectional study.
Q48158470	Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease
Q34463167	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies.
Q90860115	Genetic architecture of subcortical brain structures in 38,851 individuals
Q34709035	Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease.
Q35468938	Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer's disease.
Q26779001	Genetics Underlying Atypical Parkinsonism and Related Neurodegenerative Disorders
Q36552904	Genetics and dementia nosology
Q38310765	Genetics and underlying pathology of dementia
Q74595917	Genetics of dementia
Q38027808	Genetics of dementia: update and guidelines for the clinician
Q34811944	Genetics of parkinsonism
Q36072427	Genome-wide association study of neocortical Lewy-related pathology
Q97528167	Genome-wide screen to identify genetic loci associated with cognitive decline in late-life depression
Q28257569	Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra
Q33253340	Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration
Q37874476	Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts
Q48964629	Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies.
Q36389683	Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease
Q30421996	Gray matter atrophy associated with extrapyramidal signs in the Lewy body variant of Alzheimer's disease.
Q33183514	Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy
Q64236129	HSP90 and Its Novel Co-Chaperones, SGT1 and CHP-1, in Brain of Patients with Parkinson's Disease and Dementia with Lewy Bodies
Q35233790	Helicobacter pylori infection, dementia and primary open-angle glaucoma: are they connected?
Q39875299	High Risk of Dementia in Ventricular Enlargement with Normal Pressure Hydrocephalus Related Symptoms1.
Q92284395	High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study
Q39817537	High prevalence of dementia in a Caribbean population.
Q53316534	High white matter lesion load is associated with hippocampal atrophy in mild cognitive impairment.
Q36573060	Higher Prevalence of TDP-43 Proteinopathy in Cognitively Normal Asians: A Clinicopathological Study on a Multiethnic Sample
Q36142447	Higher cortical deficits influence attentional processing in dementia with Lewy bodies, relative to patients with dementia of the Alzheimer's type and controls
Q93353905	Higher-order spectral analysis of spontaneous speech signals in Alzheimer's disease
Q37322618	Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease
Q50860815	Hippocampal atrophy in people with memory deficits: results from the population-based IPREA study.
Q33652639	Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures.
Q37624004	Hippocampal sclerosis of aging is a key Alzheimer's disease mimic: clinical-pathologic correlations and comparisons with both alzheimer's disease and non-tauopathic frontotemporal lobar degeneration
Q37468579	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment
Q57945476	Historical landmarks in dementia with Lewy bodies
Q45133087	History of a suspected delirium is more common in dementia with Lewy bodies than Alzheimer's disease: a retrospective study.
Q34067206	History of dementia and dementia in history: an overview
Q38427228	Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a cross-sectional and longitudinal study of 55 cases
Q36271739	Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study
Q35686163	Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family
Q90717630	Hospitalization, Alzheimer's Disease and Related Neuropathologies, and Cognitive Decline
Q33449817	How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II.
Q33182448	How do memory clinics compare with traditional old age psychiatry services?
Q30999035	How to diagnose dementia with Lewy bodies: state of the art.
Q35489842	How useful is [123I]beta-CIT SPECT in clinical practice?
Q33668661	Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis
Q45099824	Hyperphosphorylated tau protein in the cerebrospinal fluid of patients with Alzheimer's disease and other dementias: preliminary findings
Q33737141	Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy.
Q48401076	Hypoperfusion of the auditory and prefrontal cortices in Parkinsonian patients with verbal hallucinations
Q53365418	Identification of families with cortical Lewy body disease.
Q33460911	Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression
Q33933189	Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method
Q38513883	Identification of proteins in human substantia nigra
Q35029469	Idiopathic rapid eye movement sleep behavior disorder is a harbinger of dementia with Lewy bodies
Q35692950	Imaging Alzheimer's disease: clinical applications
Q38368611	Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes
Q36124416	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies
Q33530076	Imaging improves diagnosis of dementia with lewy bodies
Q38734660	Imaging synucleinopathies.
Q48432894	Imaging-pathologic correlation in corticobasal degeneration
Q42493792	Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy
Q48561865	Immunohistochemical study of synphilin-1 in brains of patients with dementia with Lewy bodies - synphilin-1 is non-specifically implicated in the formation of different neuronal cytoskeletal inclusions
Q48321770	Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies
Q33811489	Immunostaining of oxidized DJ-1 in human and mouse brains
Q58793525	Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
Q48063748	Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study
Q53284283	Impact of age-related cerebral white matter changes on the transition to disability -- the LADIS study: rationale, design and methodology.
Q36144632	Impact of amyloid imaging on drug development in Alzheimer's disease
Q38794960	Impact of multiple pathologies on the threshold for clinically overt dementia
Q64237516	Impact of physical activity in vascular cognitive impairment (AFIVASC): study protocol for a randomised controlled trial
Q84581779	Impact of social network on cognitive performances and age-related cognitive decline across a 20-year follow-up
Q54974138	Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?
Q48615636	Impaired memory and executive function associated with decreased medial temporal and prefrontal blood flow in Clinical Dementia Rating 0.5 status: the Osaki-Tajiri project
Q43583704	Impaired oculomotor function in a community-based patient population with newly diagnosed idiopathic parkinsonism
Q51921749	Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease.
Q35823236	Impairments of speech fluency in Lewy body spectrum disorder
Q48203066	Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine.
Q31948953	Improvement in sundowning in dementia with Lewy bodies after treatment with donepezil
Q41474641	Improvement of Visuo-spatial Function Assessed by Raven's Colored Progressive Matrices in Dementia with Lewy Bodies by Donepezil Treatment.
Q45711964	Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA.
Q48459120	Improving actigraphic sleep estimates in insomnia and dementia: how many nights?
Q46074461	Improving the accuracy and precision of cognitive testing in mild dementia
Q46010984	In situ hybridization for detection of nocardial 16S rRNA: reactivity within intracellular inclusions in experimentally infected cynomolgus monkeys--and in Lewy body-containing human brain specimens.
Q46979979	In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.
Q34865982	In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults
Q48124638	In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies
Q55550027	Incidence and Comorbidity of Dementia with Lewy Bodies: A Population-Based Cohort Study.
Q38359613	Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb
Q33444673	Incidence and prediction of falls in dementia: a prospective study in older people
Q83117292	Incidence and predictors of excess disability in walking among nursing home residents with middle-stage dementia: a prospective cohort study
Q47614802	Incidence of dementia in elderly Latin Americans: Results of the Maracaibo Aging Study
Q36691986	Increased CSF neurogranin concentration is specific to Alzheimer disease
Q43668234	Increased alpha 2-adrenergic receptor binding in locus coeruleus projection areas in dementia with Lewy bodies.
Q48303820	Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration
Q44217822	Increased neurofibrillary tangles in the brains of older pedestrians killed in traffic accidents.
Q40615174	Individualized evaluation of cholinesterase inhibitors effects in dementia with adaptive cognitive testing.
Q35065979	Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau.
Q38493317	Influence of APOE status on lexical-semantic skills in mild cognitive impairment
Q40383156	Influence of pneumonia complications on the prognosis of patients with autopsy-confirmed Alzheimer's disease, dementia with Lewy bodies, and vascular dementia.
Q64768764	Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease
Q48325566	Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein
Q62719917	Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson’s disease
Q48431408	Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease
Q39236779	Interactions of pathological proteins in neurodegenerative diseases
Q38208255	Interleukin 6 and cognitive dysfunction.
Q34988061	Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Q50544045	Investigation of neuropsychological characteristics of very mild and mild dementia with Lewy bodies.
Q57526437	Invited comment
Q89251186	Is Braak staging valid for all types of Parkinson's disease?
Q48445688	Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease?
Q34165716	Is dementia with Lewy bodies the second most common cause of dementia?
Q33879821	Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials
Q34504659	Is synaptic loss a unique hallmark of Alzheimer's disease?
Q37522185	Is the pathology of corticobasal syndrome predictable in life?
Q36076374	Job demands and dementia risk among male twin pairs
Q33572850	Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies
Q48439664	Lack of initiative and interest in Alzheimer's disease: a single photon emission computed tomography study
Q50852841	Lack of orthostatic symptoms in dementia patients with orthostatic hypotension.
Q48259166	Laminar degeneration of frontal and temporal cortex in Parkinson disease dementia.
Q48462424	Laminar distribution of beta-amyloid deposits in dementia with Lewy bodies and in Alzheimer's disease
Q43708035	Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease
Q47138334	Late-Life Body Mass Index, Rapid Weight Loss, Apolipoprotein E ε4 and the Risk of Cognitive Decline and Incident Dementia.
Q38193541	Latest concept of Lewy body disease
Q52012955	Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study.
Q59660134	Les symptômes psychologiques et comportementaux de la démence : description et prise en charge
Q48299071	Leukocyte telomere length is linked to vascular risk factors not to Alzheimer's disease in the VITA study.
Q48631806	Levodopa improved rapid eye movement sleep behavior disorder with diffuse Lewy body disease
Q46134615	Levodopa use and sleep in patients with dementia with Lewy bodies.
Q53397047	Lewy Body Disease: Clinical and Pathological "Overlap Syndrome" Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease).
Q39243369	Lewy Body Disorders
Q34566561	Lewy bodies and dementia
Q34776843	Lewy bodies and olfactory dysfunction in old age
Q35754459	Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes
Q53257864	Lewy bodies, a misleading marker for Parkinson's disease?
Q33724257	Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions
Q35474472	Lewy body cortical involvement may not always predict dementia in Parkinson's disease
Q84012227	Lewy body dementia
Q33708670	Lewy body dementia.
Q38259709	Lewy body disease and dementia with Lewy bodies
Q37246606	Lewy body pathology in normal elderly subjects
Q48921589	Lewy body pathology involves cutaneous nerves.
Q49019858	Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders.
Q53219072	Lewy body variant of Alzheimer's disease (AD) identified by postmortem ubiquitin staining in a previously reported case of AD associated with REM sleep behavior disorder.
Q93172947	Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85
Q37420711	Ligand autoradiographical quantification of histamine H3 receptor in human dementia with Lewy bodies
Q40795880	Limbic lobe microvacuolation is minimal in Alzheimer's disease in the absence of concurrent Lewy body disease
Q50724489	Limitations for interpreting failure on individual subtests of the Montreal Cognitive Assessment.
Q48259976	Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients
Q35485586	Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease
Q31030866	Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases
Q33846330	Long-term cognitive outcome of Alzheimer's disease and dementia with Lewy bodies: dual disease is worse.
Q35114375	Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial
Q53351654	Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer's disease and Lewy body dementia.
Q42614000	Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study
Q47125731	Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study
Q35074859	Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with Lewy bodies
Q37270185	Longitudinal follow-up of late-onset Alzheimer disease families.
Q51981435	Longitudinal stability of CSF tau levels in Alzheimer patients.
Q50279725	Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies.
Q47831557	Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
Q44853727	Longitudinal testing of visual perception in dementia with Lewy bodies and Alzheimer's disease
Q44207366	Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors
Q33729642	Low sensitivity in clinical diagnoses of dementia with Lewy bodies
Q28215001	Lumping and splitting the Parkinson Plus syndromes: dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and cortical-basal ganglionic degeneration
Q48684459	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies.
Q53343525	MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease.
Q30660816	Magnetic resonance imaging and magnetic resonance spectroscopy in dementias
Q30841801	Magnetic resonance spectroscopy in the diagnosis of dementia with Lewy bodies
Q48178843	Male gender is associated with greater cerebral hypometabolism in frontotemporal dementia: evidence for sex-related cognitive reserve.
Q36847271	Management of the behavioral aspects of Parkinson's disease
Q38719967	Marinesco bodies and substantia nigra neuron density in Parkinson's disease.
Q64814783	Mass synaptometry: High-dimensional multi parametric assay for single synapses
Q48125925	Measurement of gray and white matter atrophy in dementia with Lewy bodies using diffeomorphic anatomic registration through exponentiated lie algebra: A comparison with conventional voxel-based morphometry
Q33366459	Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases
Q48819507	Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis.
Q48126466	Medial temporal regional argyrophilic grain as a possible important factor affecting dementia in Parkinson's disease
Q41200873	Mediterranean diet and cognitive health: Initial results from the Hellenic Longitudinal Investigation of Ageing and Diet
Q47604662	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study
Q35756833	Memory complaints and dementia
Q35185404	Memory profiles in pathology or biomarker confirmed Alzheimer disease and frontotemporal dementia
Q50933311	Message for caregivers of dementia with Lewy bodies patients: hallucinations can be pleasurable for your patient. Cope with your embarrassment and empathize.
Q48189574	Metabolic correlates of brain reserve in dementia with Lewy bodies: an FDG PET study.
Q34225363	Metabolic impairment of brain metabolism in patients with Lewy body dementia
Q38921067	Metals in Alzheimer's and Parkinson's Disease: Relevance to Dementia with Lewy Bodies
Q101568928	Mid to late-life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer's disease pathology at death
Q35606922	Midlife mental distress and risk for dementia up to 27 years later: the Nord-Trøndelag Health Study (HUNT) in linkage with a dementia registry in Norway
Q28386999	Midlife milk consumption and substantia nigra neuron density at death
Q37263832	Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients
Q34430750	Mild cognitive impairment predicts institutionalization among older men: a population-based cohort study
Q37882587	Milestones in Parkinson's disease--clinical and pathologic features
Q37882597	Milestones in atypical and secondary Parkinsonisms
Q48899768	Miliary brain metastases presenting as rapidly progressive dementia.
Q24187063	Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI)
Q24197659	Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI)
Q24194186	Mini-Mental State Examination (MMSE) for the detection of Alzheimer’s dementia and other dementias in asymptomatic and previously clinically unevaluated people aged over 65 years in community and primary care populations
Q24186302	Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations
Q51832764	Mini-Mental State Examination score and B-type natriuretic peptide as predictors of cardiovascular and total mortality in an elderly general population.
Q48548301	Minor depression and brain perfusion images in Parkinson's disease
Q24554351	Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies
Q35001612	Misfolded, protease-resistant proteins in animal models and human neurodegenerative disease
Q35140660	Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies
Q58693945	Mitochondrial dysfunction in Parkinson's disease
Q35693304	Modeling regional vulnerability to Alzheimer pathology
Q38642389	Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias
Q30881333	Molecular imaging biomarkers for dementia with Lewy bodies: an update
Q37462203	Molecular pathology of Lewy body diseases.
Q47301461	Monoclonal antibodies to purified cortical Lewy bodies recognize the mid-size neurofilament subunit
Q44075273	Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer's disease, and normal participants in Taiwan
Q36552119	Morphometric evaluations of the human nervous system
Q30350218	Mortality from dementia in a community-dwelling Brazilian population.
Q36225137	Motion discrimination in dementia with Lewy bodies and Alzheimer disease
Q48403039	Motor cortex inhibitory circuits in dementia with Lewy bodies and in Alzheimer's disease
Q53343520	Motor function and disability in the dementias.
Q34513753	Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies
Q42581335	Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia
Q73591758	Movement disorders
Q33816861	Movement disorders in Alzheimer's disease: more rigidity of definitions is needed
Q39694072	Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline
Q33835599	Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders
Q41965165	Multicenter population-based study on the prevalence of early onset dementia in Japan: vascular dementia as its prominent cause
Q36990181	Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias
Q40042582	Multicentre population-based dementia prevalence survey in Japan: a preliminary report
Q37157690	Multimodality Review of Amyloid-related Diseases of the Central Nervous System.
Q49139527	Multiplication of the alpha-synuclein gene is not a common disease mechanism in Lewy body disease.
Q33453702	Multiprotein deposits in neurodegenerative disorders: our experience in the tissue brain bank of Navarra
Q36739358	Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease
Q46522469	Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study
Q36745127	Multivariate spatial covariance analysis of 99mTc-exametazime SPECT images in dementia with Lewy bodies and Alzheimer's disease: utility in differential diagnosis
Q44410457	Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease
Q92135693	Nanoformulations of Herbal Extracts in Treatment of Neurodegenerative Disorders
Q46773027	Neural correlates of anosognosia for cognitive impairment in Alzheimer's disease
Q57194176	Neuritic Pathology as a Correlate of Synaptic Loss in Dementia With Lewy Bodies
Q35570812	Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies
Q46057484	Neuritic plaques in the Lewy body variant of Alzheimer disease lack paired helical filaments
Q49022747	Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease.
Q34353518	Neurobehavioral aspects of movement disorders
Q53235139	Neurocardiovascular instability, hypotensive episodes, and MRI lesions in neurodegenerative dementia.
Q37122158	Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases.
Q37468880	Neurochemical biomarkers in the differential diagnosis of movement disorders
Q35598446	Neurochemistry of consciousness: cholinergic pathologies in the human brain
Q53231429	Neurodegenerative disease: a different view of diagnosis.
Q35791523	Neurodegenerative diseases: pathology and the advantage of single-cell profiling
Q53388773	Neurodegenerative disorders in schizophrenia.
Q52983240	Neuroimaging for diagnosing dementia with Lewy bodies: What is the best neuroimaging technique in discriminating dementia with Lewy bodies from Alzheimer's disease?
Q64446743	Neuroimaging in Dementia
Q30868628	Neuroimaging in Parkinson disease: from research setting to clinical practice
Q57088961	Neuroimaging in Parkinson's disease
Q30756562	Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology
Q53222178	Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease.
Q33874305	Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia
Q47133918	Neuron-specific methylome analysis reveals epigenetic regulation and tau-related dysfunction of BRCA1 in Alzheimer's disease
Q48581887	Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein
Q35212537	Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective?
Q46017333	Neuropathologic analysis of Lewy-related α-synucleinopathy in olfactory mucosa.
Q35906341	Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN).
Q36706031	Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies
Q34063676	Neuropathologic correlates of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem MRI study
Q53366660	Neuropathologic correlates of late-onset major depression.
Q30527797	Neuropathologic substrates of Parkinson disease dementia
Q34088144	Neuropathologic substrates of ischemic vascular dementia
Q27003314	Neuropathological alterations in Alzheimer disease
Q34233138	Neuropathological analysis of lacunes and microvascular lesions in late-onset depression
Q43656306	Neuropathological and transcriptomic characteristics of the aged brain.
Q37631959	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria
Q48383261	Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias
Q74245351	Neuropathological correlates to clinically defined dementia with Lewy bodies
Q41612678	Neuropathological criteria for the diagnosis of Alzheimer's disease
Q41612685	Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies
Q40475689	Neuropathological diagnostic criteria for Alzheimer's disease.
Q48662748	Neuropathological staging of Alzheimer-related lesions: the challenge of establishing relations to age.
Q48287129	Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.
Q47724356	Neuropathology correlates of cognitive assessments
Q34262766	Neuropathology of Alzheimer's disease and other dementias
Q34079594	Neuropathology of Alzheimer's disease and related disorders
Q48346363	Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation
Q48125911	Neuropathology of cognitively normal elderly
Q57915620	Neuropathology of dementia in Parkinson's disease: A prospective, community-based study
Q51727637	Neuropathology of mild cognitive impairment.
Q41718471	Neuropathology of movement disorders.
Q37955871	Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts
Q53235380	Neuropathology of three clinical cases prospectively diagnosed as dementia with Lewy bodies.
Q34108175	Neuropsychiatric aspects of Alzheimer's disease.
Q34108197	Neuropsychiatric aspects of dementia with Lewy bodies
Q44063087	Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease
Q53293208	Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types.
Q38804275	Neuropsychiatric symptoms of cholinergic deficiency occur with degradation of the projections from the nucleus basalis of Meynert.
Q48469555	Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study
Q37212159	Neuropsychological assessment of dementia
Q37217932	Neuropsychological characterization of mild cognitive impairment
Q51912495	Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer's disease.
Q50736786	Neuropsychological patterns underlying anosognosia in people with cognitive impairment.
Q52103524	Neuropsychological performance in Alzheimer's disease and vascular dementia: comparisons in a memory clinic population.
Q51996579	Neuropsychological performance in early and late onset Alzheimer's disease: comparisons in a memory clinic population.
Q37552065	Neuropsychological profile of dementia with Lewy bodies
Q33938615	Neuropsychological study of amyotrophic lateral sclerosis and parkinsonism-dementia complex in Kii peninsula, Japan
Q24200257	Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studies
Q35105765	Neuropsychology for Movement Disorders Neurosurgery
Q37217943	Neuropsychology of dementia with Lewy bodies
Q51996492	Neuropsychosocial features of very mild Alzheimer's disease (CDR 0.5) and progression to dementia in a community: the Tajiri project.
Q53341479	Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication.
Q44573142	Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380.
Q57279173	Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases
Q34346561	Nicotinic receptor subtypes in human brain related to aging and dementia
Q48944538	Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types.
Q34156143	Nicotinic receptors in human brain: topography and pathology
Q44234633	Nicotinic receptors in the putamen of patients with dementia with Lewy bodies and Parkinson's disease: relation to changes in alpha-synuclein expression.
Q44755573	Nightmares without atonia as an early symptom of diffuse Lewy bodies disease
Q48361936	Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease.
Q34728992	No association of psychosis in Alzheimer disease with neurodegenerative pathway genes
Q53241321	No evidence of an association between CYP2D6 polymorphisms among Japanese and dementia with Lewy bodies.
Q35788235	Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.
Q35752728	Non-Alzheimer's disease dementias: anatomic, clinical, and molecular correlates
Q41199249	Non-Motor Correlates of Smoking Habits in de Novo Parkinson's Disease
Q48760446	Non-uniformity in the regional pattern of Lewy pathology in brains of dementia with Lewy bodies.
Q35789018	Nonselenium glutathione peroxidase in human brain : elevated levels in Parkinson's disease and dementia with lewy bodies
Q44177610	Nonverbal Medical Symptom Validity Test performance of elderly healthy adults and clinical neurology patients
Q48587427	Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness
Q48926109	Norms and associated factors of the STAI-Y State anxiety inventory in older adults: results from the PAQUID study.
Q39853474	Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders
Q48494226	Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases
Q48199015	Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age.
Q48198601	Nuclear factor kappa-B p50 and p65 subunits expression in dementia with Lewy bodies
Q37626224	Nucleic acid oxidation: an early feature of Alzheimer's disease
Q35463679	Occupation during life and risk of dementia in French elderly community residents
Q73571882	Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease
Q38533327	Oculo-visual changes and clinical considerations affecting older patients with dementia
Q44131513	Odor identification deficit predicts clinical conversion from mild cognitive impairment to dementia due to Alzheimer's disease
Q44573608	Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients
Q37073141	Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders
Q33728340	On telling the truth to patients with dementia
Q79463004	Orthostatic hypotension and attention in Parkinson's disease with and without dementia
Q37921665	Other dementias
Q38719322	Outcomes of Inpatient Treatment for Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease Versus Dementia With Lewy Bodies
Q51912690	Outcomes of cognitively impaired not demented at 2 years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias.
Q36117422	Overlap between neurodegenerative disorders
Q92897669	Overview of Neurocognitive Disorders
Q57211083	Overview of the Korean Longitudinal Study on Cognitive Aging and Dementia
Q35623258	Oxidative Stress and Its Clinical Applications in Dementia
Q40100862	PRNP mutations in a series of apparently sporadic neurodegenerative dementias in China
Q36124387	Pareidolias: complex visual illusions in dementia with Lewy bodies
Q48185492	Parieto-occipital glucose hypometabolism in Parkinson's disease with autonomic failure
Q35748069	Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies
Q39009679	Parkinson disease and cognitive impairment: Five new things
Q37382759	Parkinson disease with dementia: comparing patients with and without Alzheimer pathology
Q48894182	Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain.
Q38279732	Parkinson's disease as a member of Prion-like disorders
Q48922601	Parkinson's disease with late Pick's dementia.
Q34995015	Parkinson's genetics: molecular insights for the new millennium.
Q48561446	Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?
Q50283399	Partial lesion of thalamic ventral intermediate nucleus after chronic high-frequency stimulation.
Q48567127	Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification
Q36739168	Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.
Q46896067	Pathological biochemistry of alpha-synucleinopathy
Q51905667	Pathological correlates of dementia in a longitudinal, population-based sample of aging.
Q33935314	Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).
Q35579699	Pathological heterogeneity of clinically diagnosed corticobasal degeneration
Q48160818	Pathologically confirmed corticobasal degeneration presenting with visuospatial dysfunction
Q55410081	Patient- and Caregiver-Related Factors Associated with Caregiver Assessed Global Deterioration Scale Scoring in Demented Patients.
Q35462665	Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease
Q36694930	Patients with Lewy body dementia use more resources than those with Alzheimer's disease
Q49732398	Patients with dementia syndrome in public and private services in southern Brazil.
Q50980479	Patterns of gray matter atrophy in dementia with Lewy bodies: a voxel-based morphometry study.
Q38401704	Patterns of regional brain hypometabolism associated with knowledge of semantic features and categories in Alzheimer's disease.
Q35461770	Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease
Q45071383	Perception of emotion on faces in frontotemporal dementia and Alzheimer's disease: a longitudinal study
Q28346578	Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease
Q47794649	Performance and normative values of a concise neuropsychological test (CAMCOG) in an elderly population sample.
Q44665252	Performance on Standard Indexes of Effort Among Patients With Dementia
Q35476344	Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease
Q53366563	Periventricular white matter hyperintensities and the risk of dementia: a CREDOS study.
Q35599469	Pharmacologic management of psychosis in the elderly: a critical review
Q35029479	Pharmacologic therapy of dementia with Lewy bodies
Q34779344	Pharmacologic treatments of dementia
Q41838690	Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease
Q38836064	Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies.
Q34393784	Phospholipase D1 regulates autophagic flux and clearance of α-synuclein aggregates
Q39927613	Physical complications for elderly inpatients with senile dementia in the Imaise Branch of Ichinomiya City Hospital
Q24235058	Plasma and CSF Abeta for the longitudinal prediction of Alzheimer's disease dementia and other dementias in people with cognitive decline but no dementia
Q24234762	Plasma and Cerebro Spinal Fluid Amyloid Beta 42, 40 and the 42:40 ratio for diagnosis of incipient Dementia in a population with objective cognitive decline
Q24236736	Plasma and Cerebro Spinal Fluid Amyloid Beta 42, 40 and the 42:40 ratio for diagnosis of incipient Dementia in a population with objective cognitive decline
Q24201276	Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting
Q24193707	Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
Q37124508	Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study
Q81554195	Point of view: Dementia in Parkinson's disease
Q36654013	Polysomnographic findings in dementia with Lewy bodies
Q48348912	Poor cognitive outcome in shunt-responsive idiopathic normal pressure hydrocephalus
Q35994059	Poor self-rated health did not increase risk of permanent nursing placement or mortality in people with mild Alzheimer's disease
Q38006466	Positive FP-CIT SPECT (DaTSCAN) in Clinical Alzheimer's Disease - An Unexpected Finding?
Q35721063	Post mortem sampling of the brain and other tissues in neurodegenerative disease
Q36944895	Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging.
Q33952863	PrP immunohistochemistry: different protocols, including a procedure for long formalin fixation, and a proposed schematic classification for deposits in sporadic Creutzfeldt-Jakob disease
Q34974315	Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests
Q48378397	Predicting lewy body pathology in a community-based sample with clinical diagnosis of Alzheimer's disease
Q35083666	Prediction of outcomes in MCI with (123)I-IMP-CBF SPECT: a multicenter prospective cohort study
Q53290887	Predictors of cognitive impairment and dementia in older people with diabetes.
Q92762686	Predictors of mortality in Māori, Pacific Island, and European patients diagnosed with dementia at a New Zealand Memory Service
Q64999348	Predictors of prolonged hospital stay for the treatment of severe neuropsychiatric symptoms in patients with dementia: a cohort study in multiple hospitals.
Q38111335	Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease
Q48876039	Presenile dementia diagnosed as posterior cortical atrophy.
Q34649249	Presenile dementia syndromes: an update on taxonomy and diagnosis
Q34287524	Preservation of neurons of the nucleus basalis in subcortical ischemic vascular disease
Q48279657	Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.
Q57215297	Prevalence and Risk Factors of Abusive Behaviors in the Caregivers of People with Dementia in Korea
Q48496983	Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism
Q51893853	Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.
Q51867713	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Q48962165	Prevalence of Alzheimer's disease, vascular dementia and dementia with Lewy bodies in a Japanese population.
Q90397052	Prevalence of Depression, Anxiety and PTSD in People with Dementia: a Systematic Review and Meta-Analysis
Q34337167	Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort.
Q43456183	Prevalence of aging-associated cognitive decline in an Italian elderly population: results from cross-sectional phase of Italian PRoject on Epidemiology of Alzheimer's disease (IPREA).
Q48412487	Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease
Q59843505	Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia
Q37161762	Prevalence of cognitive impairment without dementia in the United States
Q46352788	Prevalence of dementia and dementia subtypes among community-dwelling elderly people in northern Nigeria
Q30583720	Prevalence of dementia and dementing diseases in the old-old population in Japan: the Kurihara Project. Implications for Long-Term Care Insurance data
Q39656405	Prevalence of dementia in a semi-urban population in Sri Lanka: report from a regional survey
Q50725526	Prevalence of dementia in elderly clients of a private health care plan: a study of the FIBRA-RJ, Brazil.
Q34584456	Prevalence of dementia in the United States: the aging, demographics, and memory study.
Q44087186	Prevalence of dementia in the older Japanese-Brazilian population
Q34551519	Prevalence of mixed pathologies in the aging brain
Q44085171	Prevalence of potentially reversible dementias in a dementia outpatient clinic of a tertiary university-affiliated hospital in Brazil
Q50713608	Prevalence of word retrieval complaint and prediction of dementia in a population-based study of elderly subjects.
Q48571581	Prevalence, incidence and risk factors of paratonia in patients with dementia: a one-year follow-up study
Q30051304	Prevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample
Q34174220	Preventing dementia
Q51850848	Previous adult attention-deficit and hyperactivity disorder symptoms and risk of dementia with Lewy bodies: a case-control study.
Q30882334	Primary Progressive Aphasia — A Language-Based Dementia
Q53381231	Primitive reflex evaluation in the clinical assessment of extrapyramidal syndromes.
Q37178758	Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases
Q44293554	Probable dementia with Lewy bodies and risperidone-induced delirium
Q46874702	Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease
Q57736159	Profiling conversation in Parkinson's disease with cognitive impairment
Q37383144	Prognostic Factors Related to Dementia with Lewy Bodies Complicated with Pneumonia: An Autopsy Study
Q38667291	Progranulin Mutations Affects Brain Oscillatory Activity in Fronto-Temporal Dementia.
Q36439004	Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary.
Q35015451	Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias--review and comparison of the cholinesterase inhibitors.
Q57255781	Progress in the classification of non-Alzheimer-type degenerative dementias
Q48659913	Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies
Q50725924	Progression and survival in Parkinson's disease with subthalamic nucleus stimulation.
Q46523791	Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.
Q64819962	Progression of falls in postmortem-confirmed parkinsonian disorders
Q34558624	Progressive supranuclear palsy: clinical features, pathophysiology and management
Q36842150	Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease.
Q41612730	Proposals for re-evaluation of current autopsy criteria for the diagnosis of Alzheimer's disease
Q42526596	Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems
Q35794541	Proteomic approach to studying Parkinson's disease
Q48098677	Proteomics identification of proteins in human cortex using multidimensional separations and MALDI tandem mass spectrometer
Q41959096	Protocol of a prospective study on the diagnostic value of transcranial duplex scanning of the substantia nigra in patients with parkinsonian symptoms
Q46708016	Proton magnetic resonance spectroscopy detects a relative decrease of N-acetylaspartate in the hippocampus of patients with dementia with Lewy bodies
Q35162966	Prototype learning and dissociable categorization systems in Alzheimer's disease
Q39732247	Proxy-rated quality of life in Alzheimer's disease: a three-year longitudinal study
Q35838935	Psychiatric aspects of Parkinson's disease--an update
Q87474279	Psychiatric symptoms typical of patients with dementia with Lewy bodies - similarity to those of levodopa-induced psychosis
Q24201053	Psychological treatments for depression and anxiety in dementia and mild cognitive impairment
Q51958551	Psychometric properties of Clock Drawing Test and MMSE or Short Performance Test (SKT) in dementia screening in a memory clinic population.
Q73965156	Psychosis Due to Neurologic Conditions
Q34543627	Psychosis in elderly patients: classification and pharmacotherapy
Q34139476	Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities.
Q35124987	Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype
Q36184471	Psychotic symptoms in Parkinson's disease. From description to etiology
Q35779329	Psychotic symptoms in Parkinson's disease: pathophysiology and management
Q38430711	Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy
Q35467266	Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer's disease.
Q51001766	Quality of dementia diagnostic evaluation for ethnic minority patients: a nationwide study.
Q43775855	Quality of life in dementia patients in Athens, Greece: predictive factors and the role of caregiver-related factors
Q30800256	Quantifying the pathology of neurodegenerative disorders: quantitative measurements, sampling strategies and data analysis
Q48319167	Quantitative analysis of neurofibrillary pathology in a general population to reappraise neuropathological criteria for senile dementia of the neurofibrillary tangle type (tangle-only dementia): the Hisayama Study
Q48632500	Quantitative neurodegenerative pathology does not explain the degree of hippocampal atrophy on MRI in degenerative dementia
Q33734079	Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts.
Q35963163	Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy
Q46171809	Quetiapine effective in treatment of inappropriate sexual behavior of lewy body disease with predominant frontal lobe signs
Q44400998	Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: A case series
Q64865094	REM Sleep Behavior Disorder (RBD) in Dementia with Lewy Bodies (DLB)
Q36441860	Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies
Q34568456	Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study
Q36894419	Rapidly progressive dementia
Q42034203	Rapidly progressive dementia
Q48218388	Rapidly progressive dementia: An eight year (2008-2016) retrospective study.
Q37393102	Rapidly progressive neurodegenerative dementias
Q37325969	Reading disorders in primary progressive aphasia: a behavioral and neuroimaging study
Q48113825	Reappraisal of a consecutive autopsy series of patients with primary degenerative dementia: Lewy-related pathology
Q31153193	Reasons for psychiatric consultation referrals in Dutch nursing home patients with dementia: a comparison with normative data on prevalence of neuropsychiatric symptoms
Q38411426	Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease
Q22242395	Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline
Q48969195	Recurrent spontaneous "neuroleptic malignant syndrome" in the absence of neuroleptic medication in probable dementia with Lewy bodies.
Q64233153	Reduced Awareness of Memory Deficit is Associated With Increased Medicare Home Health Care Use in Dementia
Q34013066	Reduced hypocretin (orexin) levels in dementia with Lewy bodies
Q55251043	Reduced vascular risk factors in Parkinson's disease dementia and dementia with Lewy bodies compared to Alzheimer's disease.
Q53126293	Reduction of Small Fibers of Thoracic Ventral Roots and Neurons of Intermediolateral Nucleus in Parkinson Disease and Dementia with Lewy Bodies.
Q53255334	Regional cerebral blood flow and EEG in clinically diagnosed dementia with Lewy bodies and Alzheimer's disease.
Q30541652	Regional cerebral blood flow change in a case of Alzheimer's disease with musical hallucinations
Q48167210	Regional cerebral blood flow in Parkinson's disease with and without dementia
Q48590317	Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography
Q53875651	Regional distribution of proteinase K-resistant alpha-synuclein correlates with Lewy body disease stage.
Q37228453	Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease
Q40643957	Relation between Resting State Front-Parietal EEG Coherence and Executive Function in Parkinson's Disease.
Q44762259	Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categories.
Q47250449	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition
Q35999098	Relationship between Postural Deformities and Frontal Function in Parkinson's Disease
Q48321578	Relationship between regional cerebral blood flow and neuropsychiatric symptoms in dementia with Lewy bodies
Q48676492	Relationship in the formation process between neurofibrillary tangles and Lewy bodies in the hippocampus of dementia with Lewy bodies brains.
Q48247020	Relationships between age and late progression of Parkinson's disease: a clinico-pathological study
Q48527031	Relative paucity of tau accumulation in the small areas with abundant Abeta42-positive capillary amyloid angiopathy within a given cortical region in the brain of patients with Alzheimer pathology
Q37393410	Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies
Q51907702	Relevance of 10-min delayed recall in dementia screening.
Q47106872	Reports by caregivers of behavioral and psychological symptoms of dementia
Q29614408	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria
Q33766569	Resilient brain aging: characterization of discordance between Alzheimer's disease pathology and cognition
Q38684552	Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies.
Q37172661	Respiratory dysrhythmia in dementia with Lewy bodies: a cross-sectional study
Q44248123	Responses to donepezil in Alzheimer's disease and Parkinson's disease
Q46459527	Reversal of head drop after discontinuation of olanzapine in a DLB patient
Q38669105	Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein
Q40630680	Revisiting DLB Diagnosis: A Consideration of Prodromal DLB and of the Diagnostic Overlap With Alzheimer Disease
Q64053060	Risk of suicide and accidental deaths among elderly patients with cognitive impairment
Q73101582	Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies
Q44654922	Rivastigmine (Exelon) for dementia in patients with Parkinson's disease
Q37556550	Rivastigmine in Parkinson's disease dementia
Q53911489	Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.
Q36300071	Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies
Q36814559	Role of DAT-SPECT in the diagnostic work up of parkinsonism
Q52964979	Role of Niemann-Pick Type C Disease Mutations in Dementia.
Q35863422	Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies
Q33985023	Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease
Q35607217	Role of dopamine transporter imaging in routine clinical practice
Q22241595	Rotenone, paraquat, and Parkinson's disease
Q33734770	Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy.
Q51937803	Screening for Alzheimer's dementia at age 78 with short psychometric instruments.
Q51952574	Screening for mild cognitive impairment (MCI) utilizing combined mini-mental-cognitive capacity examinations for identifying dementia prodromes.
Q58765564	Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: Analysis of multiple cohorts
Q43760941	Sedative load among community-dwelling people aged 75 years and older: a population-based study
Q44070760	Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease
Q59544658	Selective hippocampal neuron loss in dementia with Lewy bodies
Q48090869	Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline.
Q33670282	Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy
Q37222257	Self administered cognitive screening test (TYM) for detection of Alzheimer's disease: cross sectional study.
Q34131767	Semantic memory is impaired in both dementia with Lewy bodies and dementia of Alzheimer's type: a comparative neuropsychological study and literature review
Q48095593	Senile dementia of the neurofibrillary tangle type (tangle-only dementia): neuropathological criteria and clinical guidelines for diagnosis
Q48240563	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study
Q34648414	Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies
Q44620566	Serum markers of monocyte/macrophage activation in patients with Alzheimer's disease and other types of dementia
Q40135189	Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease
Q48487066	Severe involvement of ambient gyrus in dementia with grains
Q37684846	Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure
Q33922675	Similar ultrastructural breakdown of cerebrocortical capillaries in Alzheimer's disease, Parkinson's disease, and experimental hypertension. What is the functional link?
Q52982037	Similarity of symptoms between transient epileptic amnesia and Lewy body disease.
Q48405748	Simplified neuropathological diagnosis of dementia with Lewy bodies
Q34391742	Single photon emission CT and positron emission tomography in the evaluation of neurologic disease
Q36107762	Single-photon emission computed tomography perfusion imaging in the differential diagnosis of dementia: a retrospective regional audit
Q33604063	Size frequency distribution of the beta-amyloid (abeta) deposits in dementia with Lewy bodies with associated Alzheimer's disease pathology
Q47667861	Sleep fragmentation and Parkinson's disease pathology in older adults without Parkinson's disease.
Q38348409	Sleep-disordered breathing in dementia with Lewy bodies
Q47926474	Small-molecule PET Tracers for Imaging Proteinopathies
Q48708067	Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia.
Q34079598	Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia.
Q35610981	Spectrum of neurocognitive dysfunction in Indian population on FDG PET/CT imaging
Q38164891	Staged pathology in Parkinson's disease
Q47615614	Stages 1-2 non-rapid eye movement sleep behavior disorder associated with dementia: a new parasomnia?
Q48683712	Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium.
Q34448955	Standardized Mini-Mental State Examination. Use and interpretation.
Q36641009	Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered
Q49165313	Static and Dynamic Cognitive Reserve Proxy Measures: Interactions with Alzheimer's Disease Neuropathology and Cognition.
Q34511970	Statins and the risk of dementia
Q41345675	Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis
Q35250397	Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: a case series
Q40887919	Strategies for improving the postmortem neuropathological diagnosis of Alzheimer's disease
Q48147364	Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution
Q73222431	Striatal dopaminergic transmission and neocortical glucose utilization in Alzheimer's disease: a triple-tracer positron emission tomography study
Q44918550	Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease
Q44060087	Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias
Q30810310	Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion
Q38016600	Structure-oriented review of 14-3-3 protein isoforms in geriatric neuroscience
Q36662922	Study of visuospatial skill in patients with dementia
Q52035993	Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.
Q45781767	Subjective experiences of family caregivers of patients with dementia as predictive factors of quality of life
Q48485654	Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease
Q44852327	Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers
Q50279058	Substantia nigra tangles are related to gait impairment in older persons.
Q48628147	Subtype analysis of neuropathologically diagnosed patients in a Japanese geriatric hospital
Q34619215	Successful treatment of behavioural problems in dementia using a cholinesterase inhibitor: the ethical questions
Q32052939	Successful use of donepezil for the treatment of dementia with Lewy bodies
Q45280777	Successfully switching acetylcholinesterase inhibitor therapy in probable Lewy body dementia
Q45178246	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD.
Q35950435	Suppression of α-synuclein toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast depends on genetic context
Q38891507	Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies
Q37016518	Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of synucleinopathy
Q34748678	Synapse loss in dementias
Q44281929	Synaptic proteins and choline acetyltransferase loss in visual cortex in dementia with Lewy bodies.
Q55042971	Synucleinopathy with features of both multiple system atrophy and dementia with Lewy bodies.
Q40106095	Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects
Q41624442	T1rho (T1ρ) MR imaging in Alzheimer's disease and Parkinson's disease with and without dementia
Q47641566	TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing
Q89476365	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease
Q37315699	TDP-43 pathology, cognitive decline, and dementia in old age
Q37098471	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies
Q42502509	Tau and alpha-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs.
Q35946218	Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification
Q48190162	Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4.
Q49161817	Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.
Q55385303	Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models.
Q58478214	Tauopathies and synucleinopathies: Do cerebrospinal fluid β-amyloid peptides reflect disease-specific pathogenesis?
Q51434882	Telomere length shortening in patients with dementia with Lewy bodies.
Q37183041	Temporal course of neurodegenerative effects on cognition in old age.
Q50790456	Test Your Memory test: diagnostic utility in a memory clinic population.
Q94454182	Thalamic pulvinar metabolism, sleep disturbances, and hallucinations in dementia with Lewy bodies: positron emission tomography and actigraphy study
Q46193348	The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases
Q50732871	The Addenbrooke's Cognitive Examination Revised is as effective as the original to detect dementia in a French-speaking population.
Q57814072	The Association between White Matter Lesions on Magnetic Resonance Imaging and Noncognitive Symptoms
Q45397280	The Bedford Alzheimer nursing-severity scale to assess dementia severity in advanced dementia: a nonparametric item response analysis and a study of its psychometric characteristics
Q48662464	The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary
Q36162523	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases
Q64814715	The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders.
Q34993987	The Dutch Parelsnoer Institute--Neurodegenerative diseases; methods, design and baseline results
Q39962778	The Genetic Variability of UCP4 Affects the Individual Susceptibility to Late-Onset Alzheimer's Disease and Modifies the Disease's Risk in APOE-ɛ4 Carriers.
Q64229779	The Impact of Cerebral Amyloid Angiopathy in Various Neurodegenerative Dementia Syndromes: A Neuropathological Study
Q61076925	The Influence of Depression on Processing Speed and Executive Function in Nondemented Subjects Aged 75
Q40639780	The Institute for Ageing and Health, University of Newcastle, UK.
Q35089500	The Israel Diabetes and Cognitive Decline (IDCD) study: Design and baseline characteristics
Q34138207	The Mini-Mental State exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease
Q81237532	The Mini-SIB: a short scale for measuring cognitive function in severe dementia
Q36015683	The Pareidolia Test: A Simple Neuropsychological Test Measuring Visual Hallucination-Like Illusions
Q38866374	The Prevalence and Incidence of Dementia with Lewy Bodies: a Systematic Review
Q90048210	The Prevalence and Subtypes of Young Onset Dementia in Central Norway: A Population-Based Study
Q60712642	The Recognition, Assessment and Management of Dementing Disorders: Conclusions from the Canadian Consensus Conference on Dementia
Q53255490	The Saitohin 'Q7R' polymorphism and tau haplotype in multi-ethnic Alzheimer disease and Parkinson's disease cohorts.
Q24201440	The accuracy of 18 FDG-PET in the early diagnosis of Alzheimer’s disease dementia and other dementias in people with MCI
Q36970356	The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited
Q33183516	The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service
Q53077511	The added value of 18-fluorodeoxyglucose-positron emission tomography in the diagnosis of the behavioral variant of frontotemporal dementia.
Q35109977	The appropriate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis
Q80218708	The association of neuroleptic sensitivity in Lewy body disease with a false positive clinical diagnosis of Creutzfeldt-Jakob disease
Q80727957	The auditory startle response in parkinsonism may reveal the extent but not type of pathology
Q44580067	The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease
Q44376543	The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component.
Q40184771	The case of lost Wilma: a clinical report of Capgras delusion
Q52019569	The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's disease.
Q51987649	The clinical dementia rating sum of box score in mild dementia.
Q26849795	The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment
Q51027167	The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.
Q37611112	The concept of dementia: retain, reframe, rename or replace?
Q81791704	The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study
Q50967806	The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables.
Q34164452	The dementias
Q30712001	The diagnosis and differential diagnosis of dementia
Q31026806	The diagnosis of Parkinson's disease
Q37764258	The diagnostic accuracy of dementia-screening instruments with an administration time of 10 to 45 minutes for use in secondary care: a systematic review
Q51926890	The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders.
Q22250951	The differential diagnosis of Parkinson's disease
Q36527557	The differential impact of unique behavioral and psychological symptoms for the dementia caregiver: how and why do patients' individual symptom clusters impact caregiver depressive symptoms?
Q42490648	The distribution pattern of pathology and cholinergic deficits in amygdaloid complex in Alzheimer's disease and dementia with Lewy bodies
Q42524848	The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease.
Q42522017	The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging
Q48579743	The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?
Q61932329	The effect of age of onset of PD on risk of dementia
Q39782941	The effect of drug treatment on neurogenesis in Parkinson's disease
Q39218014	The effect of outcome information on doctors' evaluations of their own diagnostic decisions
Q38395879	The effects of behavioral and psychological symptoms on caregiver burden in frontotemporal dementia, Lewy body dementia, and Alzheimer's disease: clinical experience in China
Q35652325	The emerging role of infectious pathogens in neurodegenerative diseases
Q41614028	The epidemiology of functional psychoses of late onset
Q28744506	The evaluation of cognitive function in the dementias: methodological and regulatory considerations
Q48186751	The first autopsied case of diffuse Lewy body disease (DLBD): re-examination by recent immunostaining methods: The 50th Anniversary of Japanese Society of Neuropathology
Q48429338	The frequency and significance of 'striatal toe' in parkinsonism
Q22306301	The genetic epidemiology of neurodegenerative disease
Q34556843	The heterogeneous course of depressive symptoms for the dementia caregiver
Q41895793	The implicit function as squashing time model: a novel parallel nonlinear EEG analysis technique distinguishing mild cognitive impairment and Alzheimer's disease subjects with high degree of accuracy
Q48153916	The influence of beta-blockers on delayed memory function in people with cognitive impairment
Q48700111	The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease.
Q51993724	The initial recognition and diagnosis of dementia.
Q53370114	The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients.
Q34972009	The many faces of α-synuclein: from structure and toxicity to therapeutic target
Q48550774	The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease
Q34186331	The meteoric rise of regulated intracellular proteolysis
Q35119259	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease
Q43754058	The national DBS brain tissue network pilot study: need for more tissue and more standardization
Q52000825	The neuropsychological assessment of dementia.
Q51888583	The neuropsychological profile in dementia with Lewy bodies and Alzheimer's disease.
Q51045198	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment.
Q35136912	The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease
Q34079580	The nosology of dementia
Q35184421	The organization of narrative discourse in Lewy body spectrum disorder
Q34431680	The pathological basis of semantic dementia
Q34989485	The pathology of ischemic-vascular dementia: an update
Q45103765	The patterns of inheritance in early-onset dementia: Alzheimer's disease and frontotemporal dementia
Q57675853	The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies
Q30851659	The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans
Q31972969	The presence of FAC1 protein in Hirano bodies
Q24671745	The prevalence and causes of dementia in people under the age of 65 years
Q38259294	The prevalence and causes of younger onset dementia in Eastern Sydney, Australia
Q38092237	The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies
Q39746502	The prevalence of Parkinson's disease in an area of North Tyneside in the North-East of England
Q39834734	The prevalence of dementia in an urban Turkish population.
Q39200347	The prognosis of dementia with Lewy bodies
Q50675339	The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease.
Q51936584	The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease.
Q34679230	The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases
Q51891933	The relationship of dementia prevalence in older adults with intellectual disability (ID) to age and severity of ID.
Q44443421	The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic
Q81205485	The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodies
Q35490027	The role of levodopa in the management of dementia with Lewy bodies.
Q30652785	The role of neuroimaging in dementia
Q34063667	The role of routine laboratory studies and neuroimaging in the diagnosis of dementia: a clinicopathological study
Q35572538	The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia
Q41489155	The significance of small cerebral bleeds in neurodegenerative dementia syndromes.
Q31807516	The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease
Q33782616	The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults.
Q22242925	The spectrum of disease in chronic traumatic encephalopathy
Q22252705	The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia
Q35471099	The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDG-PET.
Q48192953	The usefulness of monitoring sleep talking for the diagnosis of Dementia with Lewy bodies
Q57813582	The utility of PAINAD in assessing pain in a UK population with severe dementia
Q61076623	The validity of amnestic MCI and non-amnestic MCI at age 75 in the prediction of Alzheimer's dementia and vascular dementia
Q51967222	The validity of clinical diagnoses of dementia in a group of consecutively autopsied memory clinic patients.
Q43030811	The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: A retrospective memory clinic study
Q35632339	The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study.
Q38667647	Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).
Q38740848	Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
Q33860727	Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies.
Q48944612	Three-dimensional stereotactic surface projection SPECT analysis in Parkinson's disease with and without dementia.
Q35454079	Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study.
Q33531705	To fold or not to fold: modulation and consequences of Hsp90 inhibition
Q54752771	Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies.
Q53275812	Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
Q28596106	Towards improving diagnosis of memory loss in general practice: TIMeLi diagnostic test accuracy study protocol
Q33710150	Trajectories of cognitive decline in Alzheimer's disease.
Q37778566	Transcranial Sonography for the Discrimination of Idiopathic Parkinson’s Disease from the Atypical Parkinsonian Syndromes
Q46750465	Transcranial magnetic stimulation for differential diagnostics in patients with parkinsonism
Q53245547	Transferrin gene polymorphism in Alzheimer's disease and dementia with Lewy bodies in humans.
Q24802281	Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype
Q35666369	Treating Psychotic Symptoms in Elderly Patients
Q28202517	Treatment interventions for Parkinson's disease: an evidence based assessment
Q36089350	Treatment of behavioural symptoms and dementia in Parkinson's disease
Q36772321	Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors
Q37552865	Treatment of dementia with lewy bodies
Q36399561	Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies
Q24291881	Tubulin seeds alpha-synuclein fibril formation
Q33984534	Tuft-shaped astrocytes in Lewy body disease
Q37377807	Twin pairs discordant for neuropathologically confirmed Lewy body dementia
Q33183359	Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study
Q38381591	Typical and atypical pathology in primary progressive aphasia variants
Q37403103	Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation
Q58478190	Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldtâ Jakob disease
Q53234560	Ubiquitin immunochemistry as a diagnostic aid for community pathologists evaluating patients who have dementia.
Q35791524	Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies
Q52538372	Ultrastructural evidence of fibrillar beta-amyloid associated with neuronal membranes in behaviorally characterized aged dog brains.
Q35038274	Unfolding the role of protein misfolding in neurodegenerative diseases
Q90028599	Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging
Q37376010	Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction
Q48318394	Unilateral spatial neglect in the late stage of Alzheimer's disease
Q81137322	Update on dementia with Lewy bodies
Q79368425	Use of psychotropics among home-dwelling nondemented and demented elderly
Q94174890	Use of the internet and of the NHS direct telephone helpline for medical information by a cognitive function clinic population
Q36142268	Usefulness of the Rowland Universal Dementia Assessment scale in South India
Q36526176	Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta
Q30836806	Using structural and diffusion magnetic resonance imaging to differentiate the dementias
Q50749211	Utility of neuropsychiatric tools in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease: quantitative and qualitative findings.
Q36373719	Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease
Q36987267	Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue
Q91673080	Validation of a European Cross-Cultural Neuropsychological Test Battery (CNTB) for evaluation of dementia
Q92555091	Validation of a brief Multicultural Cognitive Examination (MCE) for evaluation of dementia
Q53290166	Validation of a fully automated hippocampal segmentation method on patients with dementia.
Q53385153	Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
Q38877405	Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study
Q56968282	Validation of the Rowland Universal Dementia Assessment Scale (RUDAS) in a multicultural sample across five Western European countries: diagnostic accuracy and normative data
Q47721453	Validation of the Rowland Universal Dementia Assessment Scale for multicultural screening in Danish memory clinics
Q47223762	Validation of the Spanish version of the Addenbrooke's Cognitive Examination in a rural community in Spain
Q24653609	Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases
Q36906624	Validity of dementia diagnoses in the Danish hospital registers
Q92172692	Validity of screening instruments for the detection of dementia and mild cognitive impairment in hospital inpatients: A systematic review of diagnostic accuracy studies
Q77348594	Variables linked to psychotic symptoms in Alzheimer's disease
Q46233938	Vascular complications in dementia with Lewy bodies: a postmortem study
Q35163198	Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia
Q33808042	Vascular risk factors and Alzheimer's disease
Q50266619	Vascular risk factors and the effect of white matter lesions on extrapyramidal signs in Alzheimer's disease.
Q50725111	Verbal and nonverbal learning and recall in dementia with lewy bodies and Alzheimer's disease.
Q34111474	Verbal learning and memory in patients with dementia with Lewy bodies or Parkinson's disease with dementia
Q48468417	Video analysis of motor events in REM sleep behavior disorder
Q35534410	Videoconference diagnosis and management of Choctaw Indian dementia patients
Q46203563	Visual Perceptual Organization Ability in Autopsy-Verified Dementia with Lewy Bodies and Alzheimer's Disease
Q35552599	Visual assessment of posterior atrophy development of a MRI rating scale
Q35468591	Visual association test to detect early dementia of the Alzheimer type
Q44979263	Visual hallucination in Parkinson's disease with FDG PET.
Q43857756	Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies
Q47723465	Visual hallucinations in Alzheimer's disease is significantly associated with clinical diagnostic features of dementia with Lewy bodies.
Q34114062	Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe
Q37343136	Visual hallucinations in dementia: a prospective community-based study with autopsy
Q38440892	Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study
Q37974179	Visual hallucinations in the differential diagnosis of parkinsonism
Q37139055	Visual search in Dementia with Lewy Bodies and Alzheimer's disease
Q49077757	Visuospatial and visuoconstructive deficits.
Q36984659	Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies
Q47887473	Visuospatial impairment in dementia with Lewy bodies and Alzheimer's disease: a process analysis approach
Q35478942	Walking difficulties in patients with Alzheimer's disease might originate from gait apraxia.
Q33180015	What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?
Q37146578	What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?
Q37682763	What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)?
Q33195032	What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.
Q43341124	What is the prevalence of environmental hazards in the homes of dementia sufferers and are they associated with falls
Q38653824	What is the role of modifiable environmental and lifestyle risk factors in young onset dementia?
Q38088747	What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.
Q35451667	White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging
Q50216771	Why Is Later Age at Retirement Beneficial for Cognition? Results from a French Population-based Study.
Q47756736	Why do people with dementia pretend to know the correct answer? A qualitative study on the behaviour of toritsukuroi to keep up appearances
Q52568016	Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject.
Q34019790	Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course
Q35829548	Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies
Q43778565	Widespread occurrence of argyrophilic glial inclusions in Parkinson's disease
Q34195222	Work-related exposure to extremely low-frequency magnetic fields and dementia: results from the population-based study of dementia in Swedish twins
Q35420540	Would you like to know what is wrong with you? On telling the truth to patients with dementia
Q36710267	Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function
Q36834554	[(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies
Q43569268	[18F]FDG-PET study in dementia with Lewy bodies and Alzheimer's disease
Q52653445	[Alzheimer's disease with secondary Parkinson's syndrome. Case report of a patient with dementia and Parkinson's syndrome after long-term occupational exposure to insecticides, herbicides, and pesticides].
Q53269900	[Cognitive disorders and falls: experience of the Lille multidisciplinary falls service]
Q80305670	[Dementia with Lewy bodies. Clinical improvement under treatment with an acetylcholinesterase inhibitor]
Q80027950	[Hallucinations and dementia. Prevalence, clinical presentation and pathophysiology]
Q53815405	[Using the MMSE as a cognitive screener among Turkish and Moroccan migrants].
Q50671513	[Validation of the Seven Minute Screen for use in a memory clinic].
Q48366357	alpha-Synuclein pathology in the spinal cord autonomic nuclei associates with alpha-synuclein pathology in the brain: a population-based Vantaa 85+ study
Q48705293	beta-Amyloid (A beta) deposition in the medial temporal lobe of patients with dementia with Lewy bodies.
Q33947152	beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
Q34155662	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases
Q36687147	miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer's disease and other types of dementia - an exploratory study.
Q38753941	ɑ-Synuclein strains and the variable pathologies of synucleinopathies
Q42530506	α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies
Q36608855	α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease
Q57947893	α-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies

scholarly article	Q13442814
review article	Q7318358

P356	DOI	10.1212/WNL.47.5.1113
P698	PubMed publication ID	8909416

P50	author	James Lowe	Q61853326
		Suzanne S. Mirra	Q67212584
		Simon Lovestone	Q30582986
		Clive Ballard	Q40279915
		Ian G. McKeith	Q51844656
P2093	author name string	Miller BL
		Bergeron C
		Wilcock GK
		Kosaka K
		Quinn NP
		Salmon DP
		Dickson DW
		Hansen LA
		Ince PG
		Edwardson JA
		Perry EK
		Perry RH
		Burns A
		Jellinger KA
		de Vos RA
		Galasko D
		Lennox G
		Jansen EN
		Byrne EJ
		Collerton D
P433	issue	5
P407	language of work or name	English	Q1860
P921	main subject	dementia	Q83030
		dementia with Lewy bodies	Q101245788
		diagnosis	Q16644043
		workshop	Q27556165
P304	page(s)	1113-1124
P577	publication date	1996-11-01
P1433	published in	Neurology	Q1161692
P1476	title	Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop
P478	volume	47

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

scientific article

Reverse relations